<html lang="en" class="pb-page js" data-request-id="94d63d29507a36ec-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d63d29507a36ec-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/Qx-r7xaOldCxhUQMJAyA2imCL0ifQTRP5Pgld9LGLg1SjHMSZvYuaUJndJVANJWwonWUz_fuotvdN4lce5KWUQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d63d29507a36ec-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.25627361885653477"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Viral Infections|Vaccines|Childhood Diseases|Neonatology|Obstetrics/Gynecology General|Infectious Disease General|Pulmonary/Critical Care General|Pediatrics General">
<meta name="Specialties" content="Pulmonary/Critical Care|Obstetrics/Gynecology|Infectious Disease|Pediatrics"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1908380","title":"Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants","category":"Research","type":"Original Article","topics":"Viral Infections|Vaccines|Childhood Diseases|Neonatology|Obstetrics/Gynecology General|Infectious Disease General|Pulmonary/Critical Care General|Pediatrics General","specialties":"Pulmonary/Critical Care|Obstetrics/Gynecology|Infectious Disease|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-07-30T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Viral Infections|Vaccines|Childhood Diseases|Neonatology|Obstetrics/Gynecology General|Infectious Disease General|Pulmonary/Critical Care General|Pediatrics General\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Pulmonary/Critical Care|Obstetrics/Gynecology|Infectious Disease|Pediatrics\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1908380","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d63d29507a36ec-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants"><meta name="dc.Creator" content="Shabir A. Madhi"><meta name="dc.Creator" content="Fernando P. Polack"><meta name="dc.Creator" content="Pedro A. Piedra"><meta name="dc.Creator" content="Flor M. Munoz"><meta name="dc.Creator" content="Adrian A. Trenholme"><meta name="dc.Creator" content="Eric A.F. SimÃµes"><meta name="dc.Creator" content="Geeta K. Swamy"><meta name="dc.Creator" content="Sapeckshita Agrawal"><meta name="dc.Creator" content="Khatija Ahmed"><meta name="dc.Creator" content="Allison August"><meta name="dc.Creator" content="Abdullah H. Baqui"><meta name="dc.Creator" content="Anna Calvert"><meta name="dc.Creator" content="Janice Chen"><meta name="dc.Creator" content="Iksung Cho"><meta name="dc.Creator" content="Mark F. Cotton"><meta name="dc.Creator" content="Clare L. Cutland"><meta name="dc.Creator" content="Janet A. Englund"><meta name="dc.Creator" content="Amy Fix"><meta name="dc.Creator" content="Bernard Gonik"><meta name="dc.Creator" content="Laura Hammitt"><meta name="dc.Creator" content="Paul T. Heath"><meta name="dc.Creator" content="Joanne N. de Jesus"><meta name="dc.Creator" content="Christine E. Jones"><meta name="dc.Creator" content="Asma Khalil"><meta name="dc.Creator" content="David W. Kimberlin"><meta name="dc.Creator" content="Romina Libster"><meta name="dc.Creator" content="Conrado J. Llapur"><meta name="dc.Creator" content="Marilla Lucero"><meta name="dc.Creator" content="Gonzalo PÃ©rez Marc"><meta name="dc.Creator" content="Helen S. Marshall"><meta name="dc.Creator" content="Masebole S. Masenya"><meta name="dc.Creator" content="Federico MartinÃ³n-Torres"><meta name="dc.Creator" content="Jennifer K. Meece"><meta name="dc.Creator" content="Terry M. Nolan"><meta name="dc.Creator" content="Ayman Osman"><meta name="dc.Creator" content="Kirsten P. Perrett"><meta name="dc.Creator" content="Joyce S. Plested"><meta name="dc.Creator" content="Peter C. Richmond"><meta name="dc.Creator" content="Matthew D. Snape"><meta name="dc.Creator" content="Julie H. Shakib"><meta name="dc.Creator" content="Vivek Shinde"><meta name="dc.Creator" content="Tanya Stoney"><meta name="dc.Creator" content="D. Nigel Thomas"><meta name="dc.Creator" content="Alan T. Tita"><meta name="dc.Creator" content="Michael W. Varner"><meta name="dc.Creator" content="Manu Vatish"><meta name="dc.Creator" content="Keith Vrbicky"><meta name="dc.Creator" content="Judy Wen"><meta name="dc.Creator" content="Khalequ Zaman"><meta name="dc.Creator" content="Heather J. Zar"><meta name="dc.Creator" content="Gregory M. Glenn"><meta name="dc.Creator" content="Louis F. Fries"><meta name="dc.Description" content="Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most severe cases concentrated among younger infants.Healthy pregnant women,..."><meta name="Description" content="Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most severe cases concentrated among younger infants.Healthy pregnant women,..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-07-30"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1908380"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202007303830510"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa1913556"><meta name="dc.Relation" content="10.1056/NEJMe2021648"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1908380">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1908380">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1908380">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants | NEJM">
        <meta property="og:title" content="Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1908380">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/b179aa9e-55b8-462e-9a46-227c6d25f758/nejmoa1908380_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/b179aa9e-55b8-462e-9a46-227c6d25f758/nejmoa1908380_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory
tract infection in infants, with the most severe cases concentrated among younger
infants. Healthy pregnant women...">
        <meta name="twitter:description" content="Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory
tract infection in infants, with the most severe cases concentrated among younger
infants. Healthy pregnant women...">
    


    
    
        <meta property="og:image:width" content="2629">
    


    
    
        <meta property="og:image:height" content="3438">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa1908380">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1908380">
    
    







<meta name="pbContext" content=";issue:issue:doi\:10.1056/nejm_2020.383.issue-5;requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1908380;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1908380" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1908380" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1908380" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1908380" class="inputDoi"><input type="hidden" value="S.A. Madhi and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:426-439" class="inputCitation"><input type="hidden" value="07-29-2020" class="inputEPubDate"><input type="hidden" value="July 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d63d29507a36ec-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Shabir A.</span> <span property="familyName">Madhi</span>, <span property="honorificSuffix">M.B., Ch.B., F.C.Paed.(SA), Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fernando P.</span> <span property="familyName">Polack</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pedro A.</span> <span property="familyName">Piedra</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Flor M.</span> <span property="familyName">Munoz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Adrian A.</span> <span property="familyName">Trenholme</span>, <span property="honorificSuffix">M.B., F.R.A.C.P.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eric A.F.</span> <span property="familyName">SimÃµes</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Geeta K.</span> <span property="familyName">Swamy</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+45</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sapeckshita</span> <span property="familyName">Agrawal</span>, <span property="honorificSuffix">Ph.D., M.S.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Khatija</span> <span property="familyName">Ahmed</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Allison</span> <span property="familyName">August</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdullah H.</span> <span property="familyName">Baqui</span>, <span property="honorificSuffix">M.B., B.S., Dr.P.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anna</span> <span property="familyName">Calvert</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Janice</span> <span property="familyName">Chen</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Iksung</span> <span property="familyName">Cho</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark F.</span> <span property="familyName">Cotton</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Clare L.</span> <span property="familyName">Cutland</span>, <span property="honorificSuffix">M.B., B.CH., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Janet A.</span> <span property="familyName">Englund</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amy</span> <span property="familyName">Fix</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bernard</span> <span property="familyName">Gonik</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Laura</span> <span property="familyName">Hammitt</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Paul T.</span> <span property="familyName">Heath</span>, <span property="honorificSuffix">F.R.C.P.C.H.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joanne N.</span> <span property="familyName">de Jesus</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christine E.</span> <span property="familyName">Jones</span>, <span property="honorificSuffix">M.R.C.P.C.H., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Asma</span> <span property="familyName">Khalil</span>, <span property="honorificSuffix">M.D., M.R.C.O.G.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">David W.</span> <span property="familyName">Kimberlin</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Romina</span> <span property="familyName">Libster</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Conrado J.</span> <span property="familyName">Llapur</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marilla</span> <span property="familyName">Lucero</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gonzalo</span> <span property="familyName">PÃ©rez Marc</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Helen S.</span> <span property="familyName">Marshall</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Masebole S.</span> <span property="familyName">Masenya</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Federico</span> <span property="familyName">MartinÃ³n-Torres</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jennifer K.</span> <span property="familyName">Meece</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Terry M.</span> <span property="familyName">Nolan</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ayman</span> <span property="familyName">Osman</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kirsten P.</span> <span property="familyName">Perrett</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Joyce S.</span> <span property="familyName">Plested</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter C.</span> <span property="familyName">Richmond</span>, <span property="honorificSuffix">M.B., B.S., F.R.A.C.P.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Matthew D.</span> <span property="familyName">Snape</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Julie H.</span> <span property="familyName">Shakib</span>, <span property="honorificSuffix">D.O.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vivek</span> <span property="familyName">Shinde</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Tanya</span> <span property="familyName">Stoney</span>, <span property="honorificSuffix">M.B., B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">D. Nigel</span> <span property="familyName">Thomas</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alan T.</span> <span property="familyName">Tita</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael W.</span> <span property="familyName">Varner</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Manu</span> <span property="familyName">Vatish</span>, <span property="honorificSuffix">D.Phil., F.R.C.O.G.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Keith</span> <span property="familyName">Vrbicky</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Judy</span> <span property="familyName">Wen</span>, <span property="honorificSuffix">B.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Khalequ</span> <span property="familyName">Zaman</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Heather J.</span> <span property="familyName">Zar</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gregory M.</span> <span property="familyName">Glenn</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Louis F.</span> <span property="familyName">Fries</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the Prepare Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-45</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">July 29, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">426</span>-<span property="pageEnd">439</span></div><div class="doi">DOI: 10.1056/NEJMoa1908380</div><div class="core-enumeration"><a href="/toc/nejm/383/5"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">5</span></span></a></div><div><a href="#tab-information">Copyright Â© 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DShabir%2BA.%2BMadhi%252C%2BFernando%2BP.%2BPolack%252C%2BPedro%2BA.%2BPiedra%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D5%26contentID%3D10.1056%252FNEJMoa1908380%26title%3DRespiratory%2BSyncytial%2BVirus%2BVaccination%2Bduring%2BPregnancy%2Band%2BEffects%2Bin%2BInfants%26publicationDate%3D07%252F30%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1908380" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DShabir%2BA.%2BMadhi%252C%2BFernando%2BP.%2BPolack%252C%2BPedro%2BA.%2BPiedra%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D5%26contentID%3D10.1056%252FNEJMoa1908380%26title%3DRespiratory%2BSyncytial%2BVirus%2BVaccination%2Bduring%2BPregnancy%2Band%2BEffects%2Bin%2BInfants%26publicationDate%3D07%252F30%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/0702b8d4-6ec4-4ae9-b2f0-0e260db3332f/nejmoa1908380.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1908380.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908380" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1908380" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1908380.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Respiratory syncytial virus (RSV) is the dominant cause of severe lower respiratory tract infection in infants, with the most severe cases concentrated among younger infants.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 days of gestation, with an expected delivery date near the start of the RSV season, were randomly assigned in an overall ratio of approximately 2:1 to receive a single intramuscular dose of RSV fusion (F) protein nanoparticle vaccine or placebo. Infants were followed for 180 days to assess outcomes related to lower respiratory tract infection and for 364 days to assess safety. The primary end point was RSV-associated, medically significant lower respiratory tract infection up to 90 days of life, and the primary analysis of vaccine efficacy against the primary end point was performed in the per-protocol population of infants (prespecified criterion for success, lower bound of the 97.52% confidence interval [CI] of â¥30%).</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 4636 women underwent randomization, and there were 4579 live births. During the first 90 days of life, the percentage of infants with RSV-associated, medically significant lower respiratory tract infection was 1.5% in the vaccine group and 2.4% in the placebo group (vaccine efficacy, 39.4%; 97.52% CI, â1.0 to 63.7; 95% CI, 5.3 to 61.2). The corresponding percentages for RSV-associated lower respiratory tract infection with severe hypoxemia were 0.5% and 1.0% (vaccine efficacy, 48.3%; 95% CI, â8.2 to 75.3), and the percentages for hospitalization for RSV-associated lower respiratory tract infection were 2.1% and 3.7% (vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5). Local injection-site reactions among the women were more common with vaccine than with placebo (40.7% vs. 9.9%), but the percentages of participants who had other adverse events were similar in the two groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success criterion for efficacy against RSV-associated, medically significant lower respiratory tract infection in infants up to 90 days of life. The suggestion of a possible benefit with respect to other end-point events involving RSV-associated respiratory disease in infants warrants further study. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov <a href="http://clinicaltrials.gov/show/NCT02624947" target="_blank">NCT02624947</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Respiratory syncytial virus (RSV) is the dominant cause of hospitalizations in infants with lower respiratory tract infections. In 2015, an estimated 3.2 million hospitalizations for RSV-associated lower respiratory tract infection occurred in children younger than 5 years of age worldwide; 118,000 of the hospitalized children died. Approximately 44% of those hospitalizations and 46% of the in-hospital deaths occurred in infants younger than 6 months of age.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> No licensed RSV vaccine exists, and timely, active immunization against RSV infection in the first 3 to 6 months of life may be challenging. Passive immunity through transfer of IgG antibodies from immunized pregnant women offers an alternative and is endorsed by the World Health Organization (WHO) for the prevention of tetanus, influenza, and pertussis in infants.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4" id="body-ref-r4" href-manipulated="true">2-4</a></sup> Passive immunity conferred by palivizumab, a monoclonal antibody to RSV fusion (F) protein, reduced the risk of hospitalization for RSV-associated lower respiratory tract infection among premature infants and among infants with chronic lung disease or congenital heart disease,<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5" id="body-ref-r5" href-manipulated="true" aria-label="Reference 5">5</a></sup> and motavizumab (a higher-potency monoclonal antibody) reduced the risk of hospitalization for RSV-associated lower respiratory tract infection by 87% among American Indian infants born at term.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup></div><div role="paragraph">In a previous trial, recombinant RSV F protein nanoparticle vaccine (RSV F vaccine) had an acceptable safety profile when administered in pregnant women and elicited RSV A and B neutralizing antibodies, antibodies to RSV F protein site II epitope (palivizumab-competitive antibodies), and antibodies to other epitopes with broadly neutralizing activity. These antibodies were efficiently transferred to the infants.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-1" href-manipulated="true" aria-label="Reference 7">7</a></sup> Here, we describe the results of a phase 3 trial evaluating the safety and immunogenicity of RSV F vaccine in pregnant women and vaccine efficacy against RSV-associated lower respiratory tract infection in their infants through the first 90 and 180 days of life.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">A randomized, observer-blind, placebo-controlled trial was performed at 87 sites in Argentina, Australia, Chile, Bangladesh, Mexico, New Zealand, the Philippines, South Africa, Spain, the United Kingdom, and the United States. Healthy women 18 to 40 years of age with low-risk singleton pregnancies received vaccine or placebo between 28 weeks 0 days and 36 weeks 0 days of gestation, before the seasonal circulation of RSV in their locale (see Section S1.1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). Inclusion and exclusion criteria are provided in Section S1.2 and the randomization scheme in Section S1.3. The full <a href="#ap1">protocol</a> with the statistical analysis plan is also available at NEJM.org.</div><div role="paragraph">The trial staff conducted weekly active surveillance of parents or caregivers until 180 days after delivery (see Section S1.4) for the detection of symptoms of lower respiratory tract infection. Evaluations could also be triggered by spontaneous reports from the parent or caregiver. The evaluation of infants included physical examination, determination of respiratory rate, and pulse oximetry with the use of a RAD-5 pulse oximeter (Masimo) provided by the sponsor (Novavax). Nasal swab samples were obtained with the use of a nasal FLOQSwab (Copan Diagnostics) and were placed into a transport medium, stored at â70Â°C, and shipped to the Marshfield Clinic Research Institute (Marshfield, Wisconsin), where the validated eSensor RVP multiplex assay (GenMark) was used for viral diagnosis.</div><div role="paragraph">Details of the immunogenicity and safety evaluations are provided in Sections S1.5 and S1.6. RSV serologic tests included measurements of serum anti-F IgG concentrations and levels of antibodies competitive with palivizumab (i.e., antibodies that block binding of the neutralizing and protective monoclonal antibody palivizumab to RSV F protein and thus are likely to bind at or near the same site on the F protein). RSV A and B microneutralization assays have been completed in a subgroup comprising participants in the first two seasons of the trial to date; further testing is under way to examine the hypothesis that these assays may provide correlates of risk.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-2" href-manipulated="true" aria-label="Reference 7">7</a></sup></div><div role="paragraph">The sponsor designed the trial and analyzed the data with input from the investigators; the investigators collected the data and conducted the trial. The first and last authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. The investigators worked under confidentiality agreements with the sponsor.</div><div role="paragraph">The protocol was reviewed and approved by regulatory authorities in all countries and by ethical review committees at all trial sites. All the maternal participants provided written informed consent, and parental consent for the participation of infants was obtained according to the standards at each trial site. An independent data and safety monitoring board monitored safety in an unblinded manner throughout active enrollment.</div></section><section id="sec-1-2"><h3>Trial Objectives</h3><div role="paragraph">The primary objective was to show the efficacy of maternal immunization with RSV F protein vaccine for the protection of infants against RSV-associated, medically significant lower respiratory tract infection up to 90 days of life (the primary end point). RSV-associated, medically significant lower respiratory tract infection was defined as at least one manifestation of lower respiratory tract infection (cough, nasal flaring, indrawing of the lower chest wall, subcostal retractions, stridor, rales, rhonchi, wheezing, crackles or crepitations, or observed apnea) plus hypoxemia (peripheral oxygen saturation of &lt;95% at sea level or of &lt;92% at an altitude of &gt;1800 m) or tachypnea (â¥70 breaths per minute from 0 to 59 days of age and â¥60 breaths per minute at 60 days of age or older); the presence of RSV in nasal swab samples was confirmed by the central laboratory.</div><div role="paragraph">There were two secondary objectives. The first was to show vaccine efficacy against RSV-associated lower respiratory tract infection with severe hypoxemia through 90 days of life, and the second was to show vaccine efficacy against RSV-associated lower respiratory tract infection with documented hospitalization through 90 days of life. RSV-associated lower respiratory tract infection was defined as at least one manifestation of lower respiratory tract infection (cough, nasal flaring, indrawing of the lower chest wall, subcostal retractions, stridor, rales, rhonchi, wheezing, crackles or crepitations, or observed apnea). Severe hypoxemia was defined as the presence of one of the following criteria: a peripheral oxygen saturation lower than 92% at sea level or lower than 87% at an altitude greater than 1800 m or the use of high-flow nasal cannula, continuous positive airway pressure, bilevel positive airway pressure, bubble continuous positive airway pressure, bag-mask ventilation, intubation with subsequent mechanical (or manual) ventilation, or extracorporeal membrane oxygenation. Further details of the secondary objectives are provided in Section S1.7.</div><div role="paragraph">If vaccine efficacy was shown through 90 days for the primary and secondary objectives, a hierarchical sequence of hypothesis testing was to be carried out to examine vaccine efficacy up to 120, 150, and 180 days of life. Details of other secondary analyses (e.g., safety and immunogenicity), exploratory analyses (e.g., between-group differences in the percentages of infants with lower respiratory tract infection from any cause), and post hoc analyses (e.g., comparisons between high-income countries and low- or middle-income countries, as classified according to the World Bank ranking,<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> with respect to primary, secondary, and exploratory end points of lower respiratory tract infection) are provided in Section S1.8 and in the <a href="#ap1">protocol</a> and statistical analysis plan.</div></section><section id="sec-1-3"><h3>Randomization and Conduct of the Trial</h3><div role="paragraph">Randomization was performed centrally, with a separate blocking strategy for each trial site and with stratification according to maternal age (see Section S1.3). We randomly assigned women, in 1:1 ratio in the first global RSV season and in a 2:1 ratio thereafter, to receive vaccine (120 Î¼g of RSV F vaccine adsorbed to 0.4 mg of aluminum)<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-1" href-manipulated="true" aria-label="Reference 9">9</a></sup> or placebo (formulation buffer without aluminum). The trial was planned as a group-sequential design with up to two interim analyses. However, enrollment was slower than planned, and after 2 years, the sponsor elected to conduct an informational analysis (performed by the independent statistician who conducted analyses for the data and safety monitoring board). This analysis indicated that vaccine efficacy was present at a prespecified minimum level (approximately 40%) that was deemed to be sufficient to warrant further investment, with no other information provided. Enrollment was continued for a further season in the Northern and Southern Hemispheres and then terminated after enrollment in the vaccine group exceeded the minimum safety database target of 3000, at which point it was believed that a sufficient number of cases had been captured to test the primary hypothesis. End-point data that were accrued after the data lock for the informational analysis were included in the final analysis.</div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">We planned to enroll up to 8618 pregnant women on the basis of a group sequential design with two planned interim analyses with approximately 4600 and 6600 enrolled participants, a projected percentage of infants with a primary end-point event of 4% and a vaccine efficacy of approximately 60%. The primary and secondary efficacy analyses were performed in the per-protocol population, which included infants who were born at 37 weeks or more of gestation, who were born to maternal participants who had undergone randomization and received the assigned vaccine or placebo at least 2 weeks before delivery, and who did not receive prophylactic treatment with palivizumab between the day of birth and day 180 after delivery, had at least one postpartum encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding (see Section S1.9). These efficacy analyses were performed with clinical data generated by trained staff at the trial sites, including pulse oximetry measurements obtained with the sponsor-provided device; RSV diagnoses were made at the trial central laboratory with the use of the molecular assay validated for the trial. Prespecified analyses of the primary and secondary end points, based on the same data, were also performed in the intention-to-treat population, which included participants who had any visit during which efficacy data might have been gathered, regardless of treatment errors or protocol deviations.</div><div role="paragraph">In order to maximize illness ascertainment, particularly in seriously ill infants hospitalized at institutions unaffiliated with trial sites and thus not readily accessible to site staff and protocol pulse oximetry, we also performed exploratory âexpanded-dataâ intention-to-treat analyses that included physical findings, pulse oximetry data, and RSV diagnoses extracted from the medical records of infants hospitalized for respiratory or infectious illness. Further exploratory analyses of lower respiratory illnesses from any cause, irrespective of the detection of a specific pathogen, in both the per-protocol and intention-to-treat populations also used these expanded data. All primary and secondary end points, as well as exploratory end points of RSV illnesses that met the primary and secondary end-point definitions but that were evaluated with the use of expanded data, were validated by an independent adjudication committee of three pediatricians before the data were unblinded. Estimates of vaccine efficacy were calculated as percentages [(1ârelative risk)Ã100] and were based on the relative risk and confidence intervals obtained with the use of Poisson regression models with robust error variance.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup> The reported confidence intervals for secondary, exploratory, and post hoc analyses were not adjusted for multiplicity and should be viewed as descriptive and not used to infer definitive treatment effects for these end points. Vaccine efficacy against the primary end point (RSV-associated, medically significant lower respiratory tract infection) through the first 90 days of life was analyzed with the use of a one-sided type I error rate of 0.0124 based on a Pocock spending function (i.e., lower bound of a two-sided 97.52% confidence interval). This type I error rate arose from the original group-sequential design but was retained to guard against type I error inflation after the informational analysis. The Food and Drug Administration criterion for success with respect to the primary objective (i.e., to show vaccine efficacy against the primary end point) was a lower bound of the 97.52% confidence interval of 30% or greater; the criterion of other authorities was a lower bound greater than 0%. All other efficacy analyses used a 95% confidence interval, with a lower bound greater than 0% as the criterion of success (without adjustment for multiplicity).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">Between December 3, 2015, and May 2, 2018, a total of 4636 women were enrolled, of whom 3051 (65.8%) were randomly assigned to receive the RSV F vaccine (<a href="#f1">Figure 1</a>). Among the 4636 women enrolled, 52.3% were enrolled in South Africa and 23.3% were enrolled in the United States (Table S1). There were 4579 live births. Of the 4636 women, 10 (0.2%) had incomplete consent or other source documentation that could not be recovered (4 in the vaccine group and 6 in the placebo group). These participants and their infants were excluded from all analyses. A total of 4195 infants (91.6%) were included in the per-protocol population, and 4527 infants (98.9%) were included in the intention-to-treat population (<a href="#f1">Figure 1</a>). The characteristics of the women at baseline and of the infants, as well as gestational age at the time that vaccine or placebo was administered, were similar in the two trial groups (<a href="#t1">Table 1</a>), including when stratified according country income level (high-income country or low- or middle-income country) (Tables S2 and S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f1.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/b179aa9e-55b8-462e-9a46-227c6d25f758/assets/images/large/nejmoa1908380_f1.jpg" height="3438" width="2629" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Enrollment, and Randomization.</div><div class="notes"><div role="doc-footnote">Data regarding the disposition and demographic characteristics of the participants, safety, and immunogenicity were obtained from the complete and locked database (date of data extraction, September 27, 2019). Efficacy data were obtained from the locked database after all the participants had completed the 180-day follow-up (date of data extraction, January 30, 2019); these data represented the official efficacy analysis set. The safety population comprised all maternal participants who had undergone randomization and received the respiratory syncytial virus fusion protein nanoparticle vaccine (RSV F vaccine) or placebo and their live-born infants. Data on exclusions are derived from incomplete informed consent documentation, lost or incomplete source documentation, or both. The intention-to-treat efficacy analysis population included all maternal participants and their infants in the safety analysis population for whom at least one respective post-treatment or postpartum efficacy measurement was available for both the mother and the infant, as evidenced by collection of surveillance observations. The maternal participants in the per-protocol efficacy analysis population were those who received the assigned RSV F vaccine or placebo, had at least one post-treatment encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. The infant participants in the per-protocol efficacy population were those who were born at 37 weeks or more of gestation, who were born to maternal participants who had undergone randomization and received the assigned vaccine or placebo at least 2 weeks before delivery, and who did not receive prophylactic treatment with palivizumab between the day of birth and day 180 after delivery, had at least one postpartum encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. Participants who were excluded from one or more analysis populations may have had more than one of the listed major protocol deviations or exclusionary characteristics. Per-protocol status in an infant required elements of per-protocol performance in the mother.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t1.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/8153a574-4053-4068-bb56-e1e13846c619/assets/images/large/nejmoa1908380_t1.jpg" height="3438" width="1704" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">RSV F Vaccine</th><th class="txxr-borders">Placebo</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Maternal participants</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Maternal participants â no.<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">3045</td><td class="xxxr-borders">1581</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Demographic characteristics at baseline</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Maternal age â yr</td><td class="xxxx-borders">26Â±5.3</td><td class="xxxr-borders">26Â±5.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Race â no. (%)<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Black</td><td class="xxxx-borders">1335 (43.8)</td><td class="xxxr-borders">682 (43.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">903 (29.7)</td><td class="xxxr-borders shading">489 (30.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Asian</td><td class="xxxx-borders">320 (10.5)</td><td class="xxxr-borders">168 (10.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">487 (16.0)</td><td class="xxxr-borders shading">242 (15.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hispanic or Latino ethnic group â no.(%)<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">409 (13.4)</td><td class="xxxr-borders">212 (13.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Body-mass index<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">28.6Â±5.0</td><td class="xxxr-borders shading">28.5Â±5.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Primigravida â no. (%)</td><td class="xxxx-borders">1060 (34.8)</td><td class="xxxr-borders">525 (33.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">â¤3 Prior pregnancies â no. (%)</td><td class="xxxx-borders shading">2916 (95.8)</td><td class="xxxr-borders shading">1515 (95.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Other characteristics</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Gestational age at the time vaccine or placebo was administered â wk</td><td class="xxxx-borders shading">32Â±2.6</td><td class="xxxr-borders shading">32Â±2.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Method of delivery</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Vaginal â no./total no. (%)<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">2201/3007 (73.2)</td><td class="xxxr-borders shading">1132/1555 (72.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Cesarean â no./total no. (%)<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">806/3007 (26.8)</td><td class="xxxr-borders">423/1555 (27.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Data not available â no./total no. (%)</td><td class="xxxx-borders shading">38/3045 (1.2)</td><td class="xxxr-borders shading">26/1581 (1.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Infant participants</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Infant participants â no.</td><td class="xxxx-borders shading">3008</td><td class="xxxr-borders shading">1561</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Birth characteristics</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders shading">1556 (51.7)</td><td class="xxxr-borders shading">799 (51.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Interval from vaccine or placebo administration to delivery</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Mean â days</td><td class="xxxx-borders shading">51.9Â±20.4</td><td class="xxxr-borders shading">51.3Â±20.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;14 days â no. (%)</td><td class="xxxx-borders">50 (1.7)</td><td class="xxxr-borders">36 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">14 to &lt;30 days â no. (%)</td><td class="xxxx-borders shading">437 (14.5)</td><td class="xxxr-borders shading">216 (13.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">â¥30 days â no. (%)</td><td class="xxxx-borders">2521 (83.8)</td><td class="xxxr-borders">1309 (83.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Gestational age at delivery<a href="#t1fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Mean â wk</td><td class="xxxx-borders">39.3Â±1.5</td><td class="xxxr-borders">39.3Â±1.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">â¥37 wk â no./total no. (%)</td><td class="xxxx-borders shading">2811/2986 (94.1)</td><td class="xxxr-borders shading">1458/1554 (93.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;37 wk â no./total no. (%)</td><td class="xxxx-borders">175/2986 (5.9)</td><td class="xxxr-borders">96/1554 (6.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Data not available â no./total no. (%)</td><td class="xxxx-borders shading">22/3008 (0.7)</td><td class="xxxr-borders shading">7/1561 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Weight â kg</td><td class="xxxx-borders">3.2Â±0.5</td><td class="xxxr-borders">3.2Â±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Length â cm</td><td class="xxxx-borders shading">50.0Â±2.9</td><td class="xxxr-borders shading">50.2Â±3.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Frontal-occipital circumference â cm</td><td class="xxxx-borders">34.2Â±2.1</td><td class="xxxr-borders">34.2Â±1.8</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Median Apgar score (interquartile range)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">At 1 min</td><td class="xxxx-borders">9 (8â9)</td><td class="xxxr-borders">9 (8â9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">At 5 min</td><td class="xxxx-borders shading">10 (9â10)</td><td class="xxxr-borders shading">9.5 (9â10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Household characteristics at day 0 â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Infants with a smoker living in the household</td><td class="xxxx-borders shading">755 (25.1)</td><td class="xxxr-borders shading">414 (26.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Infants with other children &lt;5 yr of age living in the household</td><td class="xxxx-borders">1161 (38.6)</td><td class="xxxr-borders">618 (39.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">Infants with other children &lt;5 yr of age who attend group care â¥3 days/wk living in the household</td><td class="xbxx-borders shading">590 (19.6)</td><td class="xbxr-borders shading">326 (20.9)</td></tr></tbody></table></div><figcaption><div class="caption">Baseline Demographic Characteristics and Other Characteristics of the Maternal Participants and Birth and Household Characteristics of their Infants.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plusâminus values are means Â±SD. Percentages may not total 100 because of rounding. RSV F vaccine denotes respiratory syncytial virus fusion protein nanoparticle vaccine.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Of the 4636 maternal participants enrolled, 10 (0.2%) had incomplete consent or other source documentation that could not be recovered (4 in the vaccine group and 6 in the placebo group). These participants and their infants were excluded from all analyses.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Race was reported by the maternal participant of each motherâinfant pair for herself and for her infant.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">Ethnic group was reported by the maternal participant of each motherâinfant pair for herself and for her infant.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t1fn6" role="paragraph">Vaginal deliveries included spontaneous vaginal deliveries and forceps- or vacuum-assisted deliveries.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">Cesarean deliveries included planned repeat and primary procedures, cesarean section after failed attempts at vaginal delivery, and emergency procedures. Emergency cesarean deliveries accounted for 6.5% of all deliveries in high-income countries and for 14.5% of all deliveries in low- or middle-income countries; no effect of vaccine administration was observed in either economic stratum.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="t1fn8" role="paragraph">Gestational age at delivery was calculated only for participants for whom the protocol-mandated dating ultrasonography result was available.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary and Secondary End Points</h3><div role="paragraph">The percentage of infants who had RSV-associated, medically significant lower respiratory tract infection through 90 days was 1.5% in the vaccine group and 2.4% in the placebo group (estimated vaccine efficacy in the per-protocol analysis, 39.4%; 97.52% confidence interval [CI], â1.0 to 63.7; 95% CI, 5.3 to 61.2) (<a href="#t2">Table 2</a>). An analysis that was based on the same definition and data but that was performed in the intention-to-treat population yielded an efficacy estimate of 32.2% (95% CI, â4.2 to 55.9) (Table S15). The results of analyses that used expanded data sources in the intention-to-treat population are provided in <a href="#t2">Table 2</a>. The results for various efficacy end points in infants at 120, 150, and 180 days of life are provided in Table S14. KaplanâMeier survival curves based on analyses in the per-protocol population are provided in <a href="#f2">Figure 2</a>.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f2.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/83a76d33-9b14-4838-ad0c-7155a60343b6/assets/images/large/nejmoa1908380_f2.jpg" height="3438" width="2276" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">KaplanâMeier Survival Plots for the Primary and Secondary Efficacy End Points in the Per-Protocol Population.</div><div class="notes"><div role="doc-footnote">Shown are the KaplanâMeier survival plots for the primary efficacy end point of RSV-associated, medically significant lower respiratory tract infection (Panel A) and the secondary efficacy end points of RSV-associated lower respiratory tract infection with severe hypoxemia (Panel B) and hospitalization for RSV-associated lower respiratory tract infection (Panel C). For each panel, the main figure depicts the percentage of infants in the per-protocol population who survived without the occurrence of the specified end-point event as a function of time from delivery. Because the events under study occurred in 5% of the infant population or less over the first 180 days of life, insets are provided to show the same data on an enlarged y axis.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/992e9fc1-2b10-4091-96b0-817abe882898/assets/images/large/nejmoa1908380_t2.jpg" height="1959" width="2616" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="xxxx-borders" data-xml-align="left">Efficacy End Point</th><th class="xxxx-borders" colspan="3"><span>Per-Protocol Analyses<a href="#t2fn2" role="doc-noteref">â </a></span></th><th class="xxxx-borders" colspan="3"><span>Exploratory Expanded-Data Intention-to-Treat Analyses<a href="#t2fn3" role="doc-noteref">â¡</a></span></th></tr><tr class="head2" data-type="row head2" data-xml-valign="top"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">RSV F Vaccine</th><th class="xxxx-borders">Placebo</th><th class="xxxx-borders">Vaccine Efficacy<br>(95% CI)</th><th class="xxxx-borders">RSV F Vaccine</th><th class="xxxx-borders">Placebo</th><th class="xxxx-borders">Vaccine Efficacy<br>(95% CI)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>% of infants (no./total no.)</span></th><th class="xxxx-borders">%</th><th class="xxxx-borders" colspan="2"><span>% of infants (no./total no.)</span></th><th class="xxxx-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging01 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">RSV-associated medically significant lower respiratory tract infection up to 90 days of life</td><td class="xxxx-borders">1.5 (41/2765)</td><td class="xxxx-borders">2.4 (35/1430)</td><td class="xxxx-borders">39.4 (5.3 to 61.2)<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">2.3 (70/2980)</td><td class="xxxx-borders">4.0 (62/1547)</td><td class="xxxx-borders">41.4 (18.0 to 58.1)<a href="#t2fn5" role="doc-noteref">Â¶</a></td></tr><tr data-type="row"><td class="xxxx-borders shading"><b>Secondary end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">RSV-associated lower respiratory tract infection with severe hypoxemia up to 90 days of life</td><td class="xxxx-borders">0.5 (14/2765)</td><td class="xxxx-borders">1.0 (14/1430)</td><td class="xxxx-borders">48.3 (â8.2 to 75.3)</td><td class="xxxx-borders">0.9 (27/2980)</td><td class="xxxx-borders">2.2 (34/1547)</td><td class="xxxx-borders">58.8 (31.9 to 75.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01 shading" data-xml-align="left">Hospitalization for RSV-associated lower respiratory tract infection up to 90 days of life</td><td class="xxxx-borders shading">2.1 (57/2765)</td><td class="xxxx-borders shading">3.7 (53/1430)</td><td class="xxxx-borders shading">44.4 (19.6 to 61.5)</td><td class="xxxx-borders shading">2.2 (65/2980)</td><td class="xxxx-borders shading">4.1 (63/1547)</td><td class="xxxx-borders shading">46.4 (24.7 to 61.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01">&nbsp;</td><td class="xxxx-borders" colspan="2"><i>no. of events per 100 infants (no. of events/total no. of infants)</i></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" colspan="2"><i>no. of events per 100 infants (no. of events/total no. of infants)</i></td><td class="xxxx-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxxx-borders hanging01 shading"><b>Exploratory all-cause end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">Medically significant lower respiratory tract infection from any cause up to 90 days of life</td><td class="xxxx-borders">5.5 (153/2765)</td><td class="xxxx-borders">7.2 (103/1430)</td><td class="xxxx-borders">23.2 (1.4 to 40.2)</td><td class="xxxx-borders">5.9 (175/2980)</td><td class="xxxx-borders">7.5 (116/1547)</td><td class="xxxx-borders">21.7 (1.0 to 38.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01 shading" data-xml-align="left">Lower respiratory tract infection from any cause with severe hypoxemia up to 90 days of life</td><td class="xxxx-borders shading">1.7 (47/2765)</td><td class="xxxx-borders shading">3.1 (45/1430)</td><td class="xxxx-borders shading">46.0 (18.7 to 64.1)</td><td class="xxxx-borders shading">1.7 (51/2980)</td><td class="xxxx-borders shading">3.2 (50/1547)</td><td class="xxxx-borders shading">47.0 (21.8 to 64.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">Hospitalization for lower respiratory tract infection from any cause up to 90 days of life</td><td class="xxxx-borders">4.3 (120/2765)</td><td class="xxxx-borders">6.0 (86/1430)</td><td class="xxxx-borders">27.8 (4.8 to 45.3)</td><td class="xxxx-borders">4.2 (125/2980)</td><td class="xxxx-borders">6.6 (102/1547)</td><td class="xxxx-borders">36.4 (17.4 to 51.0)</td></tr></tbody></table></div><figcaption><div class="caption">Efficacy of Maternal Vaccination against Lower Respiratory Tract Infection in Infants.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">End-point definitions are provided in the Methods section of the article and in Sections S1.4 and S1.7 in the <a href="#ap2">Supplementary Appendix</a>. The definitions for the exploratory all-cause end points followed the definitions of primary and secondary end points but with no requirement for confirmation of RSV infection or confirmation by the clinical end-point adjudication committee. Primary and secondary end-point events and exploratory end-point events involving RSV-associated lower respiratory tract infection were reviewed and confirmed by an independent clinical end-point adjudication committee comprising not less than three pediatricians before unblinding of the data. The reported confidence intervals for vaccine efficacy were not adjusted for multiplicity and hence cannot be used to infer effects.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">The infant participants in the per-protocol efficacy population were those who were born at 37 weeks or more of gestation, who were born to maternal participants who had undergone randomization and received the assigned vaccine or placebo at least 2 weeks before delivery, and who did not receive prophylactic treatment with palivizumab between the day of birth and day 180 after delivery, had at least one postpartum encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. Primary and secondary end-point analyses in the per-protocol population were performed with the use of data based on observations from physical examination by trained clinical site personnel; pulse oximetry data that were generated with the use of the protocol-mandated Masimo Rad-5 pulse oximeter; and RSV molecular diagnostic data based on the validated GenMark eSensor assay in place at the central laboratory (Marshfield Clinic Research Institute, Marshfield, Wisconsin). All exploratory end-point analyses allowed the use of data abstracted from hospital records, as for the intention-to-treat analyses (see below).</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">The intention-to-treat population comprised all living infants with any efficacy data, regardless of gestational age, proximity of delivery to the time of maternal vaccination, or the presence of treatment errors or protocol deviations or violations. The expanded data used in the exploratory intention-to-treat analyses included the information used for primary and secondary end points as described above, supplemented by data abstracted from the hospital records of admitted participants. The intention-to-treat analysis of the primary and secondary end points that used data that were restricted to the end points evaluated according to protocol-dictated standards is reported in Table S15 in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t2fn4" role="paragraph">The 97.52% confidence interval was â1.0 to 63.7.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t2fn5" role="paragraph">The 97.52% confidence interval was 13.9 to 60.1.</div></div></div></figcaption></figure></div><div role="paragraph">The percentage of infants in the per-protocol population with RSV-associated lower respiratory tract infection with severe hypoxemia through 90 days was 0.5% in the vaccine group and 1.0% in the placebo group (vaccine efficacy, 48.3%; 95% CI, â8.2 to 75.3; vaccine efficacy in the intention-to-treat population was 44.4% (95% CI, â14.9 to 73.1), as determined with the use of clinical site data only, and 58.8% (95% CI, 31.9 to 75.0), as determined with the use of expanded data (<a href="#t2">Table 2</a> and Table S15). The percentage of infants in the per-protocol population who were hospitalized for RSV-associated lower respiratory tract infection through 90 days was 2.1% in the vaccine group and 3.7% in the placebo group (vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5); the results in the intention-to-treat population were closely similar to those of the per-protocol analysis: 48.1% (95% CI, 26.1 to 63.5), as determined with the use of clinical site data only, and 46.4% (95% CI, 24.7 to 61.9), as determined with the use of expanded data (<a href="#t2">Table 2</a> and Table S15). Point estimates of vaccine efficacy through 120, 150, and 180 days of life declined relative to the first 90 days of life with respect to the end point of RSV-associated, medically significant lower respiratory tract infection, but the estimates remained similar throughout with respect to the end points of hospitalization for RSV-associated lower respiratory tract infection and RSV-associated lower respiratory tract infection with severe hypoxemia in both the per-protocol and expanded-data intention-to-treat analyses.</div></section><section id="sec-2-3"><h3>Exploratory End Points</h3><div role="paragraph">The rate of medically significant lower respiratory tract infections from any cause through the first 90 days of life was 5.5 events per 100 infants in the vaccine group and 7.2 events per 100 in the placebo group (vaccine efficacy in the per-protocol analysis, 23.2%; 95% CI, 1.4 to 40.2) (<a href="#t2">Table 2</a>). The corresponding rates for lower respiratory tract infection from any cause with severe hypoxemia through 90 days of life were 1.7 and 3.1 events per 100 infants (vaccine efficacy, 46.0%; 95% CI, 18.7 to 64.1), and the rates for lower respiratory tract infection from any cause with hospitalization through 90 days of life were 4.3 and 6.0 events per 100 infants (vaccine efficacy, 27.8%; 95% CI, 4.8 to 45.3). The results of the expanded-data intention-to-treat analysis were similar to those of the per-protocol analysis (<a href="#t2">Table 2</a>). The effects of vaccine on lower respiratory tract infection from any cause appeared to be durable through 180 days of life.</div><div role="paragraph">Estimates of vaccine efficacy against the various end points in both per-protocol and expanded-data intention-to-treat analyses, stratified according to country income level, are provided in Table S16. Efficacy estimates were greater in low- or middle-income countries than in high-income countries in general, whereas the percentages of infants with end-point events were lower in high-income countries and the confidence bounds for vaccine efficacy estimates were therefore wider. Estimates of vaccine efficacy against lower respiratory tract infection according to RSV subtype (A or B) are provided in Table S17.</div><div role="paragraph">Estimates of vaccine efficacy against RSV-associated lower respiratory tract infection of any severity and against RSV-associated, medically significant lower respiratory tract infection according to the definition of tachypnea used by the WHO (10 breaths per minute less than in the protocol definition) were 15 to 19% over the first 90 days of life, declining to 12 to 13% over the first 180 days of life (Table S18). There was no clear efficacy against lower respiratory tract infection from any cause when events of any severity were included in the analysis. The incidence of RSV-associated symptomatic respiratory tract infection was similar among the women who received RSV F vaccine (4.9% [148 of 3004]) and among those who received placebo (4.8% [76 of 1569]) through 180 days post partum.</div></section><section id="sec-2-4"><h3>Safety</h3><div role="paragraph">Local injection-site reactions were predominantly mild and were more common among the women who received the vaccine than among those who received placebo (40.7% vs. 9.9%; P&lt;0.001) (<a href="#t3">Table 3</a> and Table S4). Fever within 7 days after vaccination occurred in 1.2% of the women who received the active vaccine and in 1.6% of the women who received placebo; the frequency of systemic reactions overall was similar in the two groups of women. No clear between-group differences were observed with regard to the percentages of women who had unsolicited adverse events, including the prespecified adverse events of special interest or adverse delivery outcomes (<a href="#t3">Table 3</a> and Section S2.2.4 and Tables S5, S7, and S9).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/64c51859-31bc-45ac-9bdd-4db2a0759c29/assets/images/large/nejmoa1908380_t3.jpg" height="2575" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders hanging03" data-xml-align="left">Adverse Event</th><th class="txxx-borders">RSV F Vaccine</th><th class="txxr-borders">Placebo</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Maternal participants reporting adverse events through the 180-day postdelivery trial visit</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Maternal participants â no.</td><td class="xxxx-borders">3045</td><td class="xxxr-borders">1581</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Any adverse event that occurred subsequent to the administration of RSV F vaccine or placebo â no. (%)</td><td class="xxxx-borders shading">2501 (82.1)</td><td class="xxxr-borders shading">1204 (76.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Solicited adverse events â no. (%)<a href="#t3fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Reactogenicity within 7 days after dosing</td><td class="xxxx-borders shading">1737 (57.0)</td><td class="xxxr-borders shading">653 (41.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Local injection-site reaction</td><td class="xxxx-borders">1240 (40.7)</td><td class="xxxr-borders">157 (9.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Systemic reaction</td><td class="xxxx-borders shading">1255 (41.2)</td><td class="xxxr-borders shading">611 (38.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Fever of any severity within 7 days after dosing</td><td class="xxxx-borders">37 (1.2)</td><td class="xxxr-borders">25 (1.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Unsolicited adverse events â no. (%)</td><td class="xxxx-borders shading">2005 (65.8)</td><td class="xxxr-borders shading">1022 (64.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Severe and related adverse event<a href="#t3fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">2 (&lt;0.1)</td><td class="xxxr-borders">4 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Medically attended adverse event</td><td class="xxxx-borders shading">1534 (50.4)</td><td class="xxxr-borders shading">802 (50.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Serious adverse event â no. (%)<a href="#t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">906 (29.8)</td><td class="xxxr-borders">455 (28.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Protocol-specified pregnancy and puerperium adverse event of special interest â no. (%)<a href="#t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">377 (12.4)</td><td class="xxxr-borders shading">190 (12.0)</td></tr><tr data-type="row"><td class="xxlx-borders"><b>Infant participants with adverse events from birth through the 364th-day-of-life trial visit</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Infant participants â no.</td><td class="xxxx-borders shading">3008</td><td class="xxxr-borders shading">1561</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Any adverse event â no. (%)</td><td class="xxxx-borders">2477 (82.3)</td><td class="xxxr-borders">1295 (83.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Severe and related adverse event<a href="#t3fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Medically attended adverse event</td><td class="xxxx-borders">2058 (68.4)</td><td class="xxxr-borders">1091 (69.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious adverse event<a href="#t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">1332 (44.3)</td><td class="xxxr-borders shading">724 (46.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Serious adverse event with outcome of death</td><td class="xxxx-borders">17 (0.6)</td><td class="xxxr-borders">12 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Protocol-specified adverse event of special interest â no. (%)<a href="#t3fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">274 (9.1)</td><td class="xxxr-borders shading">151 (9.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Serious adverse event coded to the MedDRA preferred term âpneumoniaâ â no. (%)<a href="#t3fn6" role="doc-noteref">â</a></td><td class="xbxx-borders">66 (2.2)</td><td class="xbxr-borders">70 (4.5)</td></tr></tbody></table></div><figcaption><div class="caption">Safety Profile in Maternal and Infant Participants.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Data in this table represent analyses through 180 day of postpartum follow-up for maternal participants and through 364 days of life for infant participants; there was a 14-day trial-visit window for both maternal and infant participants. Analyses were generated from the data obtained from the locked database as of September 27, 2019, and were performed in the safety analysis population (all maternal participants who had undergone randomization and received the RSV F vaccine or placebo and their live-born infants). MedDRA denotes <i>Medical Dictionary for Regulatory Activities</i>.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t3fn2" role="paragraph">Solicited adverse events were common postvaccinal adverse events that were solicited by diary from day 0 through day 6 after injection.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t3fn3" role="paragraph">Severe and related adverse events were those that substantially prevented the performance of normal daily activities and were assessed by the clinical investigators to be at least possibly related to the RSV F vaccine or placebo.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t3fn4" role="paragraph">Serious adverse events were those that were fatal or life-threatening, caused or prolonged hospitalization, led to persistent disability, or were congenital anomalies or birth defects. In this trial, all congenital anomalies, regardless of how minor, were treated as serious adverse events.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t3fn5" role="paragraph">Protocol-defined adverse events of special interest were adverse events that occurred during pregnancy and the puerperium that reflected the recommendations of the Brighton Collaboration task forces regarding safety data collection for maternal immunization.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup>.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t3fn6" role="paragraph">Serious adverse events coded to the MedDRA preferred term âpneumoniaâ showed an imbalance between the trial groups that suggested a relative risk of 0.49 in infants of immunized maternal participants, which was associated with an unadjusted P value lower than 0.001. This P value is smaller than any other in the analyses of serious adverse events by more than 2 orders of magnitude (Table S10). Further details on solicited adverse events are provided in Table S4; on unsolicited adverse events that were reported in at least 1% of maternal or infant participants in Tables S5 and S6, respectively; on all serious adverse events in maternal and infant participants in Tables S9 and S10, respectively; and all protocol-specified adverse events of special interest in maternal and infant participants in Tables S7 and S8, respectively.</div></div></div></figcaption></figure></div><div role="paragraph">The overall percentages of infants who had common or serious adverse events or protocol-defined adverse events of special interest were also similar in each trial group (<a href="#t3">Table 3</a>, and Tables S6, S8, and S10). However, serious adverse events coded as âpneumoniaâ were less common among the infants in the vaccine group (2.2%) than among those in the placebo group (4.5%) through 364 days (<a href="#t3">Table 3</a>).</div></section><section id="sec-2-5"><h3>Immunogenicity</h3><div role="paragraph">Fourteen days after injection of the RSV F vaccine (the timing of peak levels in phase 2), the geometric mean concentration of palivizumab-competitive antibodies was 12.39 times (95% CI, 11.98 to 12.81) as high as it was before injection, and the geometric mean concentration of anti-F IgG was 18.59 times (95% CI, 17.84 to 19.36) as high.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r9" id="body-ref-r9-2" href-manipulated="true">7,9</a></sup> Additional results for these antibodies as well as RSV A and B microneutralization titers are provided in Table S11. Transient decreases in RSV antibody levels in women were observed at the time of delivery; the levels rebounded at day 35 post partum and then declined at day 180 post partum.</div><div role="paragraph">The geometric mean concentrations of anti-F IgG and palivizumab-competitive antibodies in cord blood were 9501 ELISA (enzyme-linked immunosorbent assay) units (EU) per milliliter (95% CI, 9224 to 9787) and 136 Î¼g per milliliter (95% CI, 132 to 139), respectively, among the infants in the vaccine group and 752 EU per milliliter (95% CI, 719 to 786) and 15 Î¼g per milliliter (95% CI, 14 to 15), respectively, among the infants in the placebo group. In the vaccine group, the ratio of antibody concentration in cord blood to antibody concentration in the mother at the time of delivery was 1.04 (95% CI, 1.02 to 1.06) for palivizumab-competitive antibodies and 1.17 (95% CI, 1.14 to 1.19) for anti-F IgG. The estimated antibody half-life in the infants in the vaccine group was 49.1 for palivizumab-competitive antibodies and 38.3 for anti-F IgG. The results of analyses of transplacental antibody transfer overall and as stratified according to country income level are provided in Tables S11 and S12.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">We report the results of a large-scale efficacy trial of an investigational RSV F vaccine administered during pregnancy. Vaccine efficacy against RSV-associated, medically significant lower respiratory tract infection in the first 90 days of life, during which about three quarters of cases occurred, was 39% (97.52% CI, â1.0 to 63.7) in the per-protocol analysis; these results did not meet the prespecified criterion for success (lower bound of the 97.52% CI of â¥30%). Vaccine efficacy in secondary analyses was 48.3% (95% CI, â8.2 to 75.3) against RSV-associated lower respiratory tract infection with severe hypoxemia and 44.4% (95% CI, 19.6 to 61.5) against hospitalization for RSV-associated lower respiratory tract infection.</div><div role="paragraph">Although there were, as expected, more local injection-site reactions with vaccine than with placebo, the overall percentages of participants having adverse events or serious adverse events were similar in the two groups. The post hoc observation that infants born to women who received the RSV F vaccine were approximately 50% less likely to have all-cause pneumonia reported as a serious adverse event through 180 or 364 days of life is consistent with a potential benefit of the vaccine. Also suggestive of a possible benefit are the results with respect to the secondary end point of vaccine efficacy against RSV-associated lower respiratory tract infection with severe hypoxemia and the results of exploratory analyses of vaccine efficacy against hospitalization for lower respiratory tract infection from any cause and lower respiratory tract infection from any cause with severe hypoxemia in the first 90 days of life. Given their exploratory nature and the lack of adjustment for multiplicity, these analyses, as well as the expanded-data intention-to-treat analyses, should be viewed as hypothesis-generating.</div><div role="paragraph">Although the trial was not powered to evaluate vaccine efficacy according to country (or according to country income level), vaccine efficacy against RSV-associated, medically significant lower respiratory tract infection, RSV-associated lower respiratory tract infection with severe hypoxemia, and hospitalization for RSV-associated lower respiratory tract infection appeared to be greater in low- or middle-income countries than in high-income countries. However, there were substantially fewer cases and wide confidence intervals in the latter group. Further reasons for the apparent lower efficacy in high-income countries might include hospitalization for less severe cases, lower prevalence of breast-feeding, and lower background rates of severe RSV-associated lower respiratory tract infection because of factors such as less exposure to indoor smoke or to crowding and later introduction to social contact.</div><div role="paragraph">Our trial has several limitations. The study was underpowered because of overestimation of the percentage of infants who would have a primary end-point event, for which no applicable antecedent data existed, and because of the early termination of the trial. In addition, testing of cord blood for RSV A and B neutralizing antibodies has not yet been completed; the results of such testing are required to fully elucidate the association of RSV neutralizing antibody, anti-F IgG, and palivizumab-competitive antibody levels with the risk of RSV-associated lower respiratory tract infection in infants. Further analyses will attempt to establish correlates of protection against RSV-associated lower respiratory tract infection, which could inform immunogenicity-bridging studies. Additional studies are required to determine whether variation in vaccine efficacy between high-income countries and low- or middle-income countries is a consistent finding, as well as to evaluate the effectiveness of maternal RSV vaccination for the prevention of RSV-associated lower respiratory tract infection in infants born preterm.</div><div role="paragraph">In conclusion, in this randomized, placebo-controlled trial, maternal RSV F vaccine administered during pregnancy had an overall adverse event profile similar to placebo. The results with respect to the primary end point did not meet prespecified criteria for vaccine efficacy. However, the results with respect to the other end points of RSV-associated and all-cause respiratory disease in infants suggested potential benefits of maternal RSV vaccination that warrant further study of this strategy.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="version-of-record" role="paragraph">This is the <i>New England Journal of Medicine</i> version of record, which includes all <i>Journal</i> editing and enhancements. The Author Final Manuscript, which is the authorâs version after external peer review and before publication in the <i>Journal</i>, is available under a CC BY license at <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299433/" target="_blank">PMC7299433</a>.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Novavax and by a grant from the <span class="named-content" data-type="funder">Bill and Melinda Gates Foundation</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the clinical immunology laboratory staff at Novavax (Gaithersburg, Maryland) for performing enzyme-linked immunosorbent assays for respiratory syncytial virus fusion protein antibodies and assays for palivizumab-competing antibodies; the staff of the Department of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine (Houston) for performing the RSV A and B microneutralization assays; the staff of the molecular diagnostics laboratory of the Marshfield Clinic Research Institute (Marshfield, Wisconsin) for performing molecular detection of RSV; the members of the data and safety monitoring board and the clinical end-point adjudication committee; and the clinical and administrative staff at all the participating trial sites.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1908380_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1908380/suppl_file/nejmoa1908380_protocol.pdf" download="nejmoa1908380_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1908380_protocol.pdf" data-doi="10.1056/NEJMoa1908380">Download</a></li><li>5.58 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1908380_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1908380/suppl_file/nejmoa1908380_appendix.pdf" download="nejmoa1908380_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1908380_appendix.pdf" data-doi="10.1056/NEJMoa1908380">Download</a></li><li>1.66 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1908380_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1908380/suppl_file/nejmoa1908380_disclosures.pdf" download="nejmoa1908380_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1908380_disclosures.pdf" data-doi="10.1056/NEJMoa1908380">Download</a></li><li>859.95 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1908380_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1908380/suppl_file/nejmoa1908380_data-sharing.pdf" download="nejmoa1908380_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1908380_data-sharing.pdf" data-doi="10.1056/NEJMoa1908380">Download</a></li><li>67.96 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Shi T, McAllister DA, OâBrien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. <em>Lancet</em> 2017;390:946-958.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)30938-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28689664/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408746300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global%2C+regional%2C+and+national+disease+burden+estimates+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children+in+2015%3A+a+systematic+review+and+modelling+study.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=946-958&amp;doi=10.1016%2FS0140-6736%2817%2930938-8&amp;pmid=28689664" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Pertussis vaccines: WHO position paper â September 2015. <em>Wkly Epidemiol Rec</em> 2015;90:433-458.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26320265/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pertussis+vaccines%3A+WHO+position+paper+%E2%80%94+September+2015.&amp;publication_year=2015&amp;journal=Wkly+Epidemiol+Rec&amp;pages=433-458&amp;pmid=26320265" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Vaccines against influenza: WHO position paper â November 2012. <em>Wkly Epidemiol Rec</em> 2012;87:461-476.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23210147/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccines+against+influenza%3A+WHO+position+paper+%E2%80%94+November+2012.&amp;publication_year=2012&amp;journal=Wkly+Epidemiol+Rec&amp;pages=461-476&amp;pmid=23210147" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Tetanus vaccines: WHO position paper â February 2017. <em>Wkly Epidemiol Rec</em> 2017;92:53-76.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28185446/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tetanus+vaccines%3A+WHO+position+paper+%E2%80%94+February+2017.&amp;publication_year=2017&amp;journal=Wkly+Epidemiol+Rec&amp;pages=53-76&amp;pmid=28185446" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. <em>BMC Infect Dis</em> 2009;9:106-106.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2334-9-106" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19575815/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269557800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+meta-analysis+of+the+effect+of+antibody+therapy+for+the+prevention+of+severe+respiratory+syncytial+virus+infection.&amp;publication_year=2009&amp;journal=BMC+Infect+Dis&amp;pages=106-106&amp;doi=10.1186%2F1471-2334-9-106&amp;pmid=19575815" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">OâBrien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. <em>Lancet Infect Dis</em> 2015;15:1398-1408.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(15)00247-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26511956/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365144800026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+motavizumab+for+the+prevention+of+respiratory+syncytial+virus+disease+in+healthy+Native+American+infants%3A+a+phase+3+randomised+double-blind+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Lancet+Infect+Dis&amp;pages=1398-1408&amp;doi=10.1016%2FS1473-3099%2815%2900247-9&amp;pmid=26511956" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">MuÅoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. <em>J Infect Dis</em> 2019;220:1802-1815.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jiz390" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31402384/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493469600013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+respiratory+syncytial+virus+fusion+%28F%29+protein+nanoparticle+vaccine+in+healthy+third-trimester+pregnant+women+and+their+infants.&amp;publication_year=2019&amp;journal=J+Infect+Dis&amp;pages=1802-1815&amp;doi=10.1093%2Finfdis%2Fjiz390&amp;pmid=31402384" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] efficiently transferred to the infants. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] assays may provide correlates of risk. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] times (95% CI, 17.84 to 19.36) as high. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">World Bank. World Bank country and lending groups. 2020 (<a href="https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups">https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=World+Bank.+World+Bank+country+and+lending+groups.+2020+%28https%3A%2F%2Fdatahelpdesk.worldbank.org%2Fknowledgebase%2Farticles%2F906519-world-bank-country-and-lending-groups%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">August A, Glenn GM, Kpamegan E, et al. A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. <em>Vaccine</em> 2017;35:3749-3759.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2017.05.045" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28579233/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404504900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+2+randomized%2C+observer-blind%2C+placebo-controlled%2C+dose-ranging+trial+of+aluminum-adjuvanted+respiratory+syncytial+virus+F+particle+vaccine+formulations+in+healthy+women+of+childbearing+age.&amp;publication_year=2017&amp;journal=Vaccine&amp;pages=3749-3759&amp;doi=10.1016%2Fj.vaccine.2017.05.045&amp;pmid=28579233" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] F vaccine adsorbed to 0.4 mg of aluminum) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] times (95% CI, 17.84 to 19.36) as high. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Zou G. A modified Poisson regression approach to prospective studies with binary data. <em>Am J Epidemiol</em> 2004;159:702-706.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/aje/kwh090" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15033648/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000220484900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+modified+Poisson+regression+approach+to+prospective+studies+with+binary+data.&amp;publication_year=2004&amp;journal=Am+J+Epidemiol&amp;pages=702-706&amp;doi=10.1093%2Faje%2Fkwh090&amp;pmid=15033648" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Munoz FM Eckert LO, Katz MA, et al.Key terms for the assessment of the safety of vaccines in pregnancy: results of a global consultative process to initiate harmonization of adverse event definitions. <em>Vaccine</em> 2015;33:6441-6452.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2015.07.112" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26387433/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000367489300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Key+terms+for+the+assessment+of+the+safety+of+vaccines+in+pregnancy%3A+results+of+a+global+consultative+process+to+initiate+harmonization+of+adverse+event+definitions.&amp;publication_year=2015&amp;journal=Vaccine&amp;pages=6441-6452&amp;doi=10.1016%2Fj.vaccine.2015.07.112&amp;pmid=26387433" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/5"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">5</span></span> â¢ <span property="datePublished">July 30, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">426</span>-<span property="pageEnd">439</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: July 29, 2020</div><div><b class="core-label">Published in issue</b>: July 30, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/childhood-diseases" alt="View article keyword Childhood Diseases" data-interactiontype="article_recirculation_click">Childhood Diseases</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/neonatology" alt="View article keyword Neonatology" data-interactiontype="article_recirculation_click">Neonatology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/obstetrics-gynecology-general" alt="View article keyword Obstetrics/Gynecology General" data-interactiontype="article_recirculation_click">Obstetrics/Gynecology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pediatrics-general" alt="View article keyword Pediatrics General" data-interactiontype="article_recirculation_click">Pediatrics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pulmonary-critical-care-general" alt="View article keyword Pulmonary/Critical Care General" data-interactiontype="article_recirculation_click">Pulmonary/Critical Care General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/vaccines" alt="View article keyword Vaccines" data-interactiontype="article_recirculation_click">Vaccines</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/viral-infections" alt="View article keyword Viral Infections" data-interactiontype="article_recirculation_click">Viral Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Shabir A.</span> <span property="familyName">Madhi</span>, <span property="honorificSuffix">M.B., Ch.B., F.C.Paed.(SA), Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fernando P.</span> <span property="familyName">Polack</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pedro A.</span> <span property="familyName">Piedra</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Flor M.</span> <span property="familyName">Munoz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Adrian A.</span> <span property="familyName">Trenholme</span>, <span property="honorificSuffix">M.B., F.R.A.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eric A.F.</span> <span property="familyName">SimÃµes</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Geeta K.</span> <span property="familyName">Swamy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sapeckshita</span> <span property="familyName">Agrawal</span>, <span property="honorificSuffix">Ph.D., M.S.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Khatija</span> <span property="familyName">Ahmed</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Allison</span> <span property="familyName">August</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdullah H.</span> <span property="familyName">Baqui</span>, <span property="honorificSuffix">M.B., B.S., Dr.P.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anna</span> <span property="familyName">Calvert</span>, <span property="honorificSuffix">M.B., Ch.B.</span></span>, <span property="author" typeof="Person"><span property="givenName">Janice</span> <span property="familyName">Chen</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Iksung</span> <span property="familyName">Cho</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark F.</span> <span property="familyName">Cotton</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Clare L.</span> <span property="familyName">Cutland</span>, <span property="honorificSuffix">M.B., B.CH., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Janet A.</span> <span property="familyName">Englund</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amy</span> <span property="familyName">Fix</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bernard</span> <span property="familyName">Gonik</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Laura</span> <span property="familyName">Hammitt</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Paul T.</span> <span property="familyName">Heath</span>, <span property="honorificSuffix">F.R.C.P.C.H.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joanne N.</span> <span property="familyName">de Jesus</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christine E.</span> <span property="familyName">Jones</span>, <span property="honorificSuffix">M.R.C.P.C.H., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Asma</span> <span property="familyName">Khalil</span>, <span property="honorificSuffix">M.D., M.R.C.O.G.</span></span>, <span property="author" typeof="Person"><span property="givenName">David W.</span> <span property="familyName">Kimberlin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Romina</span> <span property="familyName">Libster</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Conrado J.</span> <span property="familyName">Llapur</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marilla</span> <span property="familyName">Lucero</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gonzalo</span> <span property="familyName">PÃ©rez Marc</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Helen S.</span> <span property="familyName">Marshall</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Masebole S.</span> <span property="familyName">Masenya</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Federico</span> <span property="familyName">MartinÃ³n-Torres</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jennifer K.</span> <span property="familyName">Meece</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Terry M.</span> <span property="familyName">Nolan</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ayman</span> <span property="familyName">Osman</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kirsten P.</span> <span property="familyName">Perrett</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Joyce S.</span> <span property="familyName">Plested</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter C.</span> <span property="familyName">Richmond</span>, <span property="honorificSuffix">M.B., B.S., F.R.A.C.P.</span></span>, <span property="author" typeof="Person"><span property="givenName">Matthew D.</span> <span property="familyName">Snape</span>, <span property="honorificSuffix">M.B., B.S., M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Julie H.</span> <span property="familyName">Shakib</span>, <span property="honorificSuffix">D.O.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vivek</span> <span property="familyName">Shinde</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Tanya</span> <span property="familyName">Stoney</span>, <span property="honorificSuffix">M.B., B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">D. Nigel</span> <span property="familyName">Thomas</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alan T.</span> <span property="familyName">Tita</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael W.</span> <span property="familyName">Varner</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Manu</span> <span property="familyName">Vatish</span>, <span property="honorificSuffix">D.Phil., F.R.C.O.G.</span></span>, <span property="author" typeof="Person"><span property="givenName">Keith</span> <span property="familyName">Vrbicky</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Judy</span> <span property="familyName">Wen</span>, <span property="honorificSuffix">B.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Khalequ</span> <span property="familyName">Zaman</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Heather J.</span> <span property="familyName">Zar</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gregory M.</span> <span property="familyName">Glenn</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Louis F.</span> <span property="familyName">Fries</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the Prepare Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, and the Department of Science and TechnologyâNational Research Foundation, Vaccine Preventable Diseases, University of the Witwatersrand (S.A.M., C.L.C.), and Shandukani Research Centre, Wits Reproductive Health and HIV Institute (M.S.M.), Johannesburg, Setshaba Research Centre, Soshanguve (K.A., A.O.), and the Family Centre for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg Hospital (M.F.C.), and the Department of Paediatrics and Child Health, Red Cross War Memorial Childrenâs Hospital, South African Medical Research Council Unit on Child and Adolescent Health, University of Cape Town (H.J.Z.), Cape Town â all in South Africa; FundaciÃ³n INFANT (F.P.P., R.L.), Hospital Militar Central Dr. Cosme Argerich (G.P.M.), and the National Scientific and Technical Research Council (R.L.), Buenos Aires, and the Department of Pediatric Pulmonology, Hospital del NiÃ±o JesÃºs, TucumÃ¡n (C.J.L.) â both in Argentina; the Departments of Pediatrics and Molecular Virology and Microbiology, Baylor College of Medicine, Houston (P.A.P., F.M.M.); the University of Auckland, Middlemore Hospital, Auckland, New Zealand (A.A.T.); the Department of Pediatrics, University of Colorado School of Medicine, and the Childrenâs Hospital Colorado, Center for Global Health, Colorado School of Public Health, Aurora (E.A.F.S.); the Department of Obstetrics and Gynecology, Duke University, Durham, NC (G.K.S.); Novavax (S.A., A.A., J.C., I.C., A.F., J.S.P., V.S., D.N.T., J.W., G.M.G., L.F.F.), Gaithersburg, and the Department of International Health, International Center for Maternal and Newborn Health (A.H.B.), and the Center for American Indian Health, Department of International Health (L.H.), Johns Hopkins Bloomberg School of Public Health, Baltimore â all in Maryland; the Vaccine Institute (A.C., P.T.H.) and the Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute (A.K.), St. Georgeâs, University of London, London, Paediatric Infectious Diseases, Clinical and Experimental Sciences, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton (C.E.J.), and the Oxford Vaccine Group, Department of Paediatrics, University of Oxford and National Institute for Health Research Oxford Biomedical Research Centre (M.D.S.), and the Nuffield Department of Womenâs and Reproductive Health, University of Oxford (M.V.), Oxford â all in the United Kingdom; the Department of Pediatrics, Seattle Childrenâs Hospital, University of Washington, Seattle (J.A.E.);the Department of Obstetrics and Gynecology, Wayne State University, Detroit (B.G.); the Research Institute for Tropical Medicine, Muntinlupa, Philippines (J.N.J., M.L.); the Department of Pediatrics (D.W.K.) and the Division of MaternalâFetal Medicine, Department of Obstetrics and Gynecology and Center for Womenâs Reproductive Health (A.T.T.), University of Alabama, Birmingham; the Womenâs and Childrenâs Hospital and Robinson Research Institute, University of Adelaide, Adelaide, SA (H.S.M.), the Melbourne School of Population and Global Health, University of Melbourne, and Murdoch Childrenâs Research Institute, Parkville, VIC (T.M.N., K.P.P.), and Wesfarmers Center of Vaccines and Infectious Diseases, Telethon Kids Institute, Division of Paediatrics, School of Medicine, University of Western Australia, Perth Childrenâs Hospital, Perth (P.C.R., T.S.) â all in Australia; Marshfield Clinic Research Institute, Marshfield, WI (J.K.M.); PediatrÃ­a ClÃ­nica, InfectologÃ­a y Traslacional Hospital ClÃ­nico Universitario de Santiago de Compostela, Santiago de Compostela, Spain (F.M.-T.); the Division of General Pediatrics, Department of Pediatrics, School of Medicine (J.H.S.), and the Department of Obstetrics and Gynecology (M.W.V.), University of Utah Health Sciences Center, Salt Lake City; Meridian Clinical Research, Norfolk, NE (K.V.); and the International Center for Diarrhoeal Disease Research Bangladesh, Dhaka (K.Z.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Fries at Novavax, 22 Firstfield Rd., Gaithersburg, MD 20878, or at <a href="mailto:lfries@novavax.com">lfries@novavax.com</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the investigators in the Prepare Study Group is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">314</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1908380" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="2a36c792-6c9a-bd3a-3ee7-44a977c6029b"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633" style="display:inline-block;">
                <img alt="Article has an altmetric score of 249" src="https://badges.altmetric.com/?size=320&amp;score=249&amp;types=mbttttwd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_2a36c792-6c9a-bd3a-3ee7-44a977c6029b" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633&amp;tab=news">
          Picked up by <b>15</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633&amp;tab=twitter">
          Posted by <b>153</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=86771633&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>209</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d63d29507a36ec-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1908380"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-5%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1908380%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="314" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yizi Zhou, </li><li class="list-inline-item cited-by__entry__author">Zhan Gao, </li><li class="list-inline-item cited-by__entry__author">Zepeng He, </li><li class="list-inline-item cited-by__entry__author">Zhenfu Wen, </li><li class="list-inline-item cited-by__entry__author">Zhihui Zhang, </li><li class="list-inline-item cited-by__entry__author">Xuanli Jin, </li><li class="list-inline-item cited-by__entry__author">Hong Liu, </li><li class="list-inline-item cited-by__entry__author">Zhijia Liu, </li><li class="list-inline-item cited-by__entry__author">Lixin Liu, </li><li class="list-inline-item cited-by__entry__author">Yongming Chen, </li></ul><span class="cited-by__entry__title">Nanoparticulate lipid adjuvants induce robust immunity against RSV infectionçº³ç±³é¢ç²èè´¨ä½åæ¿åæRSVææçå¼ºæåç«ä¿æ¤, </span><span class="cited-by__entry__series-title">Science China Materials, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40843-025-3404-8" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40843-025-3404-8</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40843-025-3404-8" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">S. Haggie, </li><li class="list-inline-item cited-by__entry__author">I.M. Balfour-Lynn, </li></ul><span class="cited-by__entry__title">Outcomes of paediatric community acquired pneumonia, </span><span class="cited-by__entry__series-title">Paediatric Respiratory Reviews, </span><span class="cited-by__entry__volume"><strong>54</strong>, </span><span class="cited-by__entry__page-range">(3-11), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prrv.2024.10.003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prrv.2024.10.003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prrv.2024.10.003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lisa Frigati, </li><li class="list-inline-item cited-by__entry__author">Leonore Greybe, </li><li class="list-inline-item cited-by__entry__author">Savvas Andronikou, </li><li class="list-inline-item cited-by__entry__author">Ernst Eber, </li><li class="list-inline-item cited-by__entry__author">Shyam Sunder B. Venkatakrishna, </li><li class="list-inline-item cited-by__entry__author">Pierre Goussard, </li></ul><span class="cited-by__entry__title">Respiratory infections in low and middle-income countries, </span><span class="cited-by__entry__series-title">Paediatric Respiratory Reviews, </span><span class="cited-by__entry__volume"><strong>54</strong>, </span><span class="cited-by__entry__page-range">(43-51), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.prrv.2024.08.002" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.prrv.2024.08.002</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.prrv.2024.08.002" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ping-Ing Lee, </li><li class="list-inline-item cited-by__entry__author">Yhu-Chering Huang, </li><li class="list-inline-item cited-by__entry__author">Chih-Jung Chen, </li><li class="list-inline-item cited-by__entry__author">Cheng-Hsun Chiu, </li><li class="list-inline-item cited-by__entry__author">Po-Yen Chen, </li><li class="list-inline-item cited-by__entry__author">Chun-Yi Lu, </li><li class="list-inline-item cited-by__entry__author">Ching-Chuan Liu, </li><li class="list-inline-item cited-by__entry__author">Nan-Chang Chiu, </li><li class="list-inline-item cited-by__entry__author">Hsin Chi, </li><li class="list-inline-item cited-by__entry__author">Chien-Yu Lin, </li><li class="list-inline-item cited-by__entry__author">Chun Yi Lee, </li><li class="list-inline-item cited-by__entry__author">Shuenn-Nan Chiu, </li><li class="list-inline-item cited-by__entry__author">Mei-Jy Jeng, </li><li class="list-inline-item cited-by__entry__author">Kuang-Che Kuo, </li><li class="list-inline-item cited-by__entry__author">Ren-Bin Tang, </li><li class="list-inline-item cited-by__entry__author">Yung-Feng Huang, </li><li class="list-inline-item cited-by__entry__author">Hui-Hsien Pan, </li><li class="list-inline-item cited-by__entry__author">Ming-Fang Cheng, </li><li class="list-inline-item cited-by__entry__author">Li-Min Huang, </li><li class="list-inline-item cited-by__entry__author">Ya-Li Hu, </li><li class="list-inline-item cited-by__entry__author">Tzou-Yien Lin, </li></ul><span class="cited-by__entry__title">Recommendation for immune prophylaxis of respiratory syncytial virus infection in children, </span><span class="cited-by__entry__series-title">Journal of Microbiology, Immunology and Infection, </span><span class="cited-by__entry__volume"><strong>58</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__page-range">(288-293), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jmii.2025.02.007" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jmii.2025.02.007</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jmii.2025.02.007" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Olyvia J. Jasset, </li><li class="list-inline-item cited-by__entry__author">Paola Andrea Lopez Zapana, </li><li class="list-inline-item cited-by__entry__author">Zeynep Bahadir, </li><li class="list-inline-item cited-by__entry__author">Lydia Shook, </li><li class="list-inline-item cited-by__entry__author">Maria Dennis, </li><li class="list-inline-item cited-by__entry__author">Emily Gilbert, </li><li class="list-inline-item cited-by__entry__author">Zhaojing Ariel Liu, </li><li class="list-inline-item cited-by__entry__author">Rachel V. Yinger, </li><li class="list-inline-item cited-by__entry__author">Caroline Bald, </li><li class="list-inline-item cited-by__entry__author">Caroline G. Bradford, </li><li class="list-inline-item cited-by__entry__author">Alexa H. Silfen, </li><li class="list-inline-item cited-by__entry__author">Sabra L. Klein, </li><li class="list-inline-item cited-by__entry__author">Andrew Pekosz, </li><li class="list-inline-item cited-by__entry__author">Sallie Permar, </li><li class="list-inline-item cited-by__entry__author">Liza Konnikova, </li><li class="list-inline-item cited-by__entry__author">Lael M. Yonker, </li><li class="list-inline-item cited-by__entry__author">Douglas Lauffenburger, </li><li class="list-inline-item cited-by__entry__author">Ashley Nelson, </li><li class="list-inline-item cited-by__entry__author">Michal A. Elovitz, </li><li class="list-inline-item cited-by__entry__author">Andrea G. Edlow, </li></ul><span class="cited-by__entry__title">Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth, </span><span class="cited-by__entry__series-title">American Journal of Obstetrics and Gynecology, </span><span class="cited-by__entry__volume"><strong>232</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(554.e1-554.e15), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ajog.2024.10.053" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ajog.2024.10.053</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ajog.2024.10.053" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Peter Selley, </li><li class="list-inline-item cited-by__entry__author">David Healy, </li></ul><span class="cited-by__entry__title">The Health of Pregnant Women and Their Unborn Childrenâ Neglected in Vaccine Development, </span><span class="cited-by__entry__series-title">Birth Defects Research, </span><span class="cited-by__entry__volume"><strong>117</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/bdr2.2483" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/bdr2.2483</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/bdr2.2483" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sophia Aguiar Monteiro Borges, </li><li class="list-inline-item cited-by__entry__author">Natacha Regina de Moraes Cerchiari, </li><li class="list-inline-item cited-by__entry__author">Erick Ohanesian Polli, </li><li class="list-inline-item cited-by__entry__author">Ana Carolina Nonato, </li><li class="list-inline-item cited-by__entry__author">Felipe Lima Barreto, </li><li class="list-inline-item cited-by__entry__author">Alexandre de Oliveira Esteves, </li><li class="list-inline-item cited-by__entry__author">Maarten Jacobus Postma, </li><li class="list-inline-item cited-by__entry__author">Ana Marli Christovam Sartori, </li><li class="list-inline-item cited-by__entry__author">PatrÃ­cia Coelho de SoÃ¡rez, </li></ul><span class="cited-by__entry__title">Disease burden estimates in economic evaluation studies of respiratory syncytial virus (RSV) maternal immunization: a systematic review, </span><span class="cited-by__entry__series-title">Expert Review of Pharmacoeconomics &amp; Outcomes Research, </span><span class="cited-by__entry__page-range">(1-34), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/14737167.2025.2498663" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14737167.2025.2498663</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14737167.2025.2498663" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Tatiana S. Kotomina, </li></ul><span class="cited-by__entry__title">Current status of developments in the field of respiratory syncytial virus vaccines, </span><span class="cited-by__entry__series-title">Journal of microbiology, epidemiology and immunobiology, </span><span class="cited-by__entry__volume"><strong>102</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(239-264), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.36233/0372-9311-675" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.36233/0372-9311-675</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.36233/0372-9311-675" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Aviraj K. S, </li><li class="list-inline-item cited-by__entry__author">Apoorva Wasnik, </li><li class="list-inline-item cited-by__entry__author">Lalima Gupta, </li><li class="list-inline-item cited-by__entry__author">Ayushi Ranjan, </li><li class="list-inline-item cited-by__entry__author">Harshini Suresh, </li></ul><span class="cited-by__entry__title">Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis, </span><span class="cited-by__entry__series-title">Systematic Reviews, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s13643-025-02856-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s13643-025-02856-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s13643-025-02856-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dina Mrcela, </li><li class="list-inline-item cited-by__entry__author">Shuyu Deng, </li><li class="list-inline-item cited-by__entry__author">You Li, </li><li class="list-inline-item cited-by__entry__author">Ivana Jukic, </li><li class="list-inline-item cited-by__entry__author">Josko Markic, </li></ul><span class="cited-by__entry__title">Knowledge, attitudes, and practices of Croatian pediatricians and pediatrics residents about RSV infection, </span><span class="cited-by__entry__series-title">Scientific Reports, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41598-025-01021-2" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41598-025-01021-2</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41598-025-01021-2" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-5%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1908380%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1908380" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1908380" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1908380.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f1.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/b179aa9e-55b8-462e-9a46-227c6d25f758/assets/images/large/nejmoa1908380_f1.jpg" height="3438" width="2629" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Enrollment, and Randomization.</div><div class="notes"><div role="doc-footnote">Data regarding the disposition and demographic characteristics of the participants, safety, and immunogenicity were obtained from the complete and locked database (date of data extraction, September 27, 2019). Efficacy data were obtained from the locked database after all the participants had completed the 180-day follow-up (date of data extraction, January 30, 2019); these data represented the official efficacy analysis set. The safety population comprised all maternal participants who had undergone randomization and received the respiratory syncytial virus fusion protein nanoparticle vaccine (RSV F vaccine) or placebo and their live-born infants. Data on exclusions are derived from incomplete informed consent documentation, lost or incomplete source documentation, or both. The intention-to-treat efficacy analysis population included all maternal participants and their infants in the safety analysis population for whom at least one respective post-treatment or postpartum efficacy measurement was available for both the mother and the infant, as evidenced by collection of surveillance observations. The maternal participants in the per-protocol efficacy analysis population were those who received the assigned RSV F vaccine or placebo, had at least one post-treatment encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. The infant participants in the per-protocol efficacy population were those who were born at 37 weeks or more of gestation, who were born to maternal participants who had undergone randomization and received the assigned vaccine or placebo at least 2 weeks before delivery, and who did not receive prophylactic treatment with palivizumab between the day of birth and day 180 after delivery, had at least one postpartum encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. Participants who were excluded from one or more analysis populations may have had more than one of the listed major protocol deviations or exclusionary characteristics. Per-protocol status in an infant required elements of per-protocol performance in the mother.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f2.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/83a76d33-9b14-4838-ad0c-7155a60343b6/assets/images/large/nejmoa1908380_f2.jpg" height="3438" width="2276" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">KaplanâMeier Survival Plots for the Primary and Secondary Efficacy End Points in the Per-Protocol Population.</div><div class="notes"><div role="doc-footnote">Shown are the KaplanâMeier survival plots for the primary efficacy end point of RSV-associated, medically significant lower respiratory tract infection (Panel A) and the secondary efficacy end points of RSV-associated lower respiratory tract infection with severe hypoxemia (Panel B) and hospitalization for RSV-associated lower respiratory tract infection (Panel C). For each panel, the main figure depicts the percentage of infants in the per-protocol population who survived without the occurrence of the specified end-point event as a function of time from delivery. Because the events under study occurred in 5% of the infant population or less over the first 180 days of life, insets are provided to show the same data on an enlarged y axis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1908380/asset/8153a574-4053-4068-bb56-e1e13846c619/assets/images/large/nejmoa1908380_t1.jpg" height="3438" width="1704" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">RSV F Vaccine</th><th class="txxr-borders">Placebo</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>Maternal participants</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Maternal participants â no.<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">3045</td><td class="xxxr-borders">1581</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Demographic characteristics at baseline</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Maternal age â yr</td><td class="xxxx-borders">26Â±5.3</td><td class="xxxr-borders">26Â±5.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Race â no. (%)<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Black</td><td class="xxxx-borders">1335 (43.8)</td><td class="xxxr-borders">682 (43.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">White</td><td class="xxxx-borders shading">903 (29.7)</td><td class="xxxr-borders shading">489 (30.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Asian</td><td class="xxxx-borders">320 (10.5)</td><td class="xxxr-borders">168 (10.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">487 (16.0)</td><td class="xxxr-borders shading">242 (15.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hispanic or Latino ethnic group â no.(%)<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">409 (13.4)</td><td class="xxxr-borders">212 (13.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">28.6Â±5.0</td><td class="xxxr-borders shading">28.5Â±5.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Primigravida â no. (%)</td><td class="xxxx-borders">1060 (34.8)</td><td class="xxxr-borders">525 (33.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">â¤3 Prior pregnancies â no. (%)</td><td class="xxxx-borders shading">2916 (95.8)</td><td class="xxxr-borders shading">1515 (95.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Other characteristics</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Gestational age at the time vaccine or placebo was administered â wk</td><td class="xxxx-borders shading">32Â±2.6</td><td class="xxxr-borders shading">32Â±2.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Method of delivery</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Vaginal â no./total no. (%)<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">2201/3007 (73.2)</td><td class="xxxr-borders shading">1132/1555 (72.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Cesarean â no./total no. (%)<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">806/3007 (26.8)</td><td class="xxxr-borders">423/1555 (27.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Data not available â no./total no. (%)</td><td class="xxxx-borders shading">38/3045 (1.2)</td><td class="xxxr-borders shading">26/1581 (1.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Infant participants</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Infant participants â no.</td><td class="xxxx-borders shading">3008</td><td class="xxxr-borders shading">1561</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Birth characteristics</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders shading">1556 (51.7)</td><td class="xxxr-borders shading">799 (51.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Interval from vaccine or placebo administration to delivery</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Mean â days</td><td class="xxxx-borders shading">51.9Â±20.4</td><td class="xxxr-borders shading">51.3Â±20.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;14 days â no. (%)</td><td class="xxxx-borders">50 (1.7)</td><td class="xxxr-borders">36 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">14 to &lt;30 days â no. (%)</td><td class="xxxx-borders shading">437 (14.5)</td><td class="xxxr-borders shading">216 (13.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">â¥30 days â no. (%)</td><td class="xxxx-borders">2521 (83.8)</td><td class="xxxr-borders">1309 (83.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Gestational age at delivery<a href="#core-t1fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Mean â wk</td><td class="xxxx-borders">39.3Â±1.5</td><td class="xxxr-borders">39.3Â±1.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">â¥37 wk â no./total no. (%)</td><td class="xxxx-borders shading">2811/2986 (94.1)</td><td class="xxxr-borders shading">1458/1554 (93.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;37 wk â no./total no. (%)</td><td class="xxxx-borders">175/2986 (5.9)</td><td class="xxxr-borders">96/1554 (6.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Data not available â no./total no. (%)</td><td class="xxxx-borders shading">22/3008 (0.7)</td><td class="xxxr-borders shading">7/1561 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Weight â kg</td><td class="xxxx-borders">3.2Â±0.5</td><td class="xxxr-borders">3.2Â±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Length â cm</td><td class="xxxx-borders shading">50.0Â±2.9</td><td class="xxxr-borders shading">50.2Â±3.1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Frontal-occipital circumference â cm</td><td class="xxxx-borders">34.2Â±2.1</td><td class="xxxr-borders">34.2Â±1.8</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Median Apgar score (interquartile range)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">At 1 min</td><td class="xxxx-borders">9 (8â9)</td><td class="xxxr-borders">9 (8â9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">At 5 min</td><td class="xxxx-borders shading">10 (9â10)</td><td class="xxxr-borders shading">9.5 (9â10)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Household characteristics at day 0 â no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Infants with a smoker living in the household</td><td class="xxxx-borders shading">755 (25.1)</td><td class="xxxr-borders shading">414 (26.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Infants with other children &lt;5 yr of age living in the household</td><td class="xxxx-borders">1161 (38.6)</td><td class="xxxr-borders">618 (39.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">Infants with other children &lt;5 yr of age who attend group care â¥3 days/wk living in the household</td><td class="xbxx-borders shading">590 (19.6)</td><td class="xbxr-borders shading">326 (20.9)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plusâminus values are means Â±SD. Percentages may not total 100 because of rounding. RSV F vaccine denotes respiratory syncytial virus fusion protein nanoparticle vaccine.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Of the 4636 maternal participants enrolled, 10 (0.2%) had incomplete consent or other source documentation that could not be recovered (4 in the vaccine group and 6 in the placebo group). These participants and their infants were excluded from all analyses.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Race was reported by the maternal participant of each motherâinfant pair for herself and for her infant.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Ethnic group was reported by the maternal participant of each motherâinfant pair for herself and for her infant.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Vaginal deliveries included spontaneous vaginal deliveries and forceps- or vacuum-assisted deliveries.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">Cesarean deliveries included planned repeat and primary procedures, cesarean section after failed attempts at vaginal delivery, and emergency procedures. Emergency cesarean deliveries accounted for 6.5% of all deliveries in high-income countries and for 14.5% of all deliveries in low- or middle-income countries; no effect of vaccine administration was observed in either economic stratum.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">Gestational age at delivery was calculated only for participants for whom the protocol-mandated dating ultrasonography result was available.</div></div></div></figcaption></a><figcaption><div class="caption">Baseline Demographic Characteristics and Other Characteristics of the Maternal Participants and Birth and Household Characteristics of their Infants.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1908380/asset/992e9fc1-2b10-4091-96b0-817abe882898/assets/images/large/nejmoa1908380_t2.jpg" height="1959" width="2616" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="xxxx-borders" data-xml-align="left">Efficacy End Point</th><th class="xxxx-borders" colspan="3"><span>Per-Protocol Analyses<a href="#core-t2fn2" role="doc-noteref">â </a></span></th><th class="xxxx-borders" colspan="3"><span>Exploratory Expanded-Data Intention-to-Treat Analyses<a href="#core-t2fn3" role="doc-noteref">â¡</a></span></th></tr><tr class="head2" data-type="row head2" data-xml-valign="top"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">RSV F Vaccine</th><th class="xxxx-borders">Placebo</th><th class="xxxx-borders">Vaccine Efficacy<br>(95% CI)</th><th class="xxxx-borders">RSV F Vaccine</th><th class="xxxx-borders">Placebo</th><th class="xxxx-borders">Vaccine Efficacy<br>(95% CI)</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>% of infants (no./total no.)</span></th><th class="xxxx-borders">%</th><th class="xxxx-borders" colspan="2"><span>% of infants (no./total no.)</span></th><th class="xxxx-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxxx-borders hanging01 shading"><b>Primary end point</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">RSV-associated medically significant lower respiratory tract infection up to 90 days of life</td><td class="xxxx-borders">1.5 (41/2765)</td><td class="xxxx-borders">2.4 (35/1430)</td><td class="xxxx-borders">39.4 (5.3 to 61.2)<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">2.3 (70/2980)</td><td class="xxxx-borders">4.0 (62/1547)</td><td class="xxxx-borders">41.4 (18.0 to 58.1)<a href="#core-t2fn5" role="doc-noteref">Â¶</a></td></tr><tr data-type="row"><td class="xxxx-borders shading"><b>Secondary end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">RSV-associated lower respiratory tract infection with severe hypoxemia up to 90 days of life</td><td class="xxxx-borders">0.5 (14/2765)</td><td class="xxxx-borders">1.0 (14/1430)</td><td class="xxxx-borders">48.3 (â8.2 to 75.3)</td><td class="xxxx-borders">0.9 (27/2980)</td><td class="xxxx-borders">2.2 (34/1547)</td><td class="xxxx-borders">58.8 (31.9 to 75.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01 shading" data-xml-align="left">Hospitalization for RSV-associated lower respiratory tract infection up to 90 days of life</td><td class="xxxx-borders shading">2.1 (57/2765)</td><td class="xxxx-borders shading">3.7 (53/1430)</td><td class="xxxx-borders shading">44.4 (19.6 to 61.5)</td><td class="xxxx-borders shading">2.2 (65/2980)</td><td class="xxxx-borders shading">4.1 (63/1547)</td><td class="xxxx-borders shading">46.4 (24.7 to 61.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01">&nbsp;</td><td class="xxxx-borders" colspan="2"><i>no. of events per 100 infants (no. of events/total no. of infants)</i></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders" colspan="2"><i>no. of events per 100 infants (no. of events/total no. of infants)</i></td><td class="xxxx-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxxx-borders hanging01 shading"><b>Exploratory all-cause end points</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">Medically significant lower respiratory tract infection from any cause up to 90 days of life</td><td class="xxxx-borders">5.5 (153/2765)</td><td class="xxxx-borders">7.2 (103/1430)</td><td class="xxxx-borders">23.2 (1.4 to 40.2)</td><td class="xxxx-borders">5.9 (175/2980)</td><td class="xxxx-borders">7.5 (116/1547)</td><td class="xxxx-borders">21.7 (1.0 to 38.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01 shading" data-xml-align="left">Lower respiratory tract infection from any cause with severe hypoxemia up to 90 days of life</td><td class="xxxx-borders shading">1.7 (47/2765)</td><td class="xxxx-borders shading">3.1 (45/1430)</td><td class="xxxx-borders shading">46.0 (18.7 to 64.1)</td><td class="xxxx-borders shading">1.7 (51/2980)</td><td class="xxxx-borders shading">3.2 (50/1547)</td><td class="xxxx-borders shading">47.0 (21.8 to 64.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging01" data-xml-align="left">Hospitalization for lower respiratory tract infection from any cause up to 90 days of life</td><td class="xxxx-borders">4.3 (120/2765)</td><td class="xxxx-borders">6.0 (86/1430)</td><td class="xxxx-borders">27.8 (4.8 to 45.3)</td><td class="xxxx-borders">4.2 (125/2980)</td><td class="xxxx-borders">6.6 (102/1547)</td><td class="xxxx-borders">36.4 (17.4 to 51.0)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"><div class="label">*</div></a><div id="core-t2fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg">End-point definitions are provided in the Methods section of the article and in Sections S1.4 and S1.7 in the </a><a href="#ap2">Supplementary Appendix</a>. The definitions for the exploratory all-cause end points followed the definitions of primary and secondary end points but with no requirement for confirmation of RSV infection or confirmation by the clinical end-point adjudication committee. Primary and secondary end-point events and exploratory end-point events involving RSV-associated lower respiratory tract infection were reviewed and confirmed by an independent clinical end-point adjudication committee comprising not less than three pediatricians before unblinding of the data. The reported confidence intervals for vaccine efficacy were not adjusted for multiplicity and hence cannot be used to infer effects.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The infant participants in the per-protocol efficacy population were those who were born at 37 weeks or more of gestation, who were born to maternal participants who had undergone randomization and received the assigned vaccine or placebo at least 2 weeks before delivery, and who did not receive prophylactic treatment with palivizumab between the day of birth and day 180 after delivery, had at least one postpartum encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. Primary and secondary end-point analyses in the per-protocol population were performed with the use of data based on observations from physical examination by trained clinical site personnel; pulse oximetry data that were generated with the use of the protocol-mandated Masimo Rad-5 pulse oximeter; and RSV molecular diagnostic data based on the validated GenMark eSensor assay in place at the central laboratory (Marshfield Clinic Research Institute, Marshfield, Wisconsin). All exploratory end-point analyses allowed the use of data abstracted from hospital records, as for the intention-to-treat analyses (see below).</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The intention-to-treat population comprised all living infants with any efficacy data, regardless of gestational age, proximity of delivery to the time of maternal vaccination, or the presence of treatment errors or protocol deviations or violations. The expanded data used in the exploratory intention-to-treat analyses included the information used for primary and secondary end points as described above, supplemented by data abstracted from the hospital records of admitted participants. The intention-to-treat analysis of the primary and secondary end points that used data that were restricted to the end points evaluated according to protocol-dictated standards is reported in Table S15 in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The 97.52% confidence interval was â1.0 to 63.7.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">The 97.52% confidence interval was 13.9 to 60.1.</div></div></div></figcaption><figcaption><div class="caption">Efficacy of Maternal Vaccination against Lower Respiratory Tract Infection in Infants.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1908380/asset/64c51859-31bc-45ac-9bdd-4db2a0759c29/assets/images/large/nejmoa1908380_t3.jpg" height="2575" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1" data-xml-valign="top"><th class="txlx-borders hanging03" data-xml-align="left">Adverse Event</th><th class="txxx-borders">RSV F Vaccine</th><th class="txxr-borders">Placebo</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders shading"><b>Maternal participants reporting adverse events through the 180-day postdelivery trial visit</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Maternal participants â no.</td><td class="xxxx-borders">3045</td><td class="xxxr-borders">1581</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Any adverse event that occurred subsequent to the administration of RSV F vaccine or placebo â no. (%)</td><td class="xxxx-borders shading">2501 (82.1)</td><td class="xxxr-borders shading">1204 (76.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Solicited adverse events â no. (%)<a href="#core-t3fn2" role="doc-noteref">â </a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Reactogenicity within 7 days after dosing</td><td class="xxxx-borders shading">1737 (57.0)</td><td class="xxxr-borders shading">653 (41.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Local injection-site reaction</td><td class="xxxx-borders">1240 (40.7)</td><td class="xxxr-borders">157 (9.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Systemic reaction</td><td class="xxxx-borders shading">1255 (41.2)</td><td class="xxxr-borders shading">611 (38.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Fever of any severity within 7 days after dosing</td><td class="xxxx-borders">37 (1.2)</td><td class="xxxr-borders">25 (1.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Unsolicited adverse events â no. (%)</td><td class="xxxx-borders shading">2005 (65.8)</td><td class="xxxr-borders shading">1022 (64.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Severe and related adverse event<a href="#core-t3fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">2 (&lt;0.1)</td><td class="xxxr-borders">4 (0.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Medically attended adverse event</td><td class="xxxx-borders shading">1534 (50.4)</td><td class="xxxr-borders shading">802 (50.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Serious adverse event â no. (%)<a href="#core-t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">906 (29.8)</td><td class="xxxr-borders">455 (28.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Protocol-specified pregnancy and puerperium adverse event of special interest â no. (%)<a href="#core-t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">377 (12.4)</td><td class="xxxr-borders shading">190 (12.0)</td></tr><tr data-type="row"><td class="xxlx-borders"><b>Infant participants with adverse events from birth through the 364th-day-of-life trial visit</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Infant participants â no.</td><td class="xxxx-borders shading">3008</td><td class="xxxr-borders shading">1561</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Any adverse event â no. (%)</td><td class="xxxx-borders">2477 (82.3)</td><td class="xxxr-borders">1295 (83.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Severe and related adverse event<a href="#core-t3fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Medically attended adverse event</td><td class="xxxx-borders">2058 (68.4)</td><td class="xxxr-borders">1091 (69.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious adverse event<a href="#core-t3fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">1332 (44.3)</td><td class="xxxr-borders shading">724 (46.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Serious adverse event with outcome of death</td><td class="xxxx-borders">17 (0.6)</td><td class="xxxr-borders">12 (0.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Protocol-specified adverse event of special interest â no. (%)<a href="#core-t3fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">274 (9.1)</td><td class="xxxr-borders shading">151 (9.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging03" data-xml-align="left">Serious adverse event coded to the MedDRA preferred term âpneumoniaâ â no. (%)<a href="#core-t3fn6" role="doc-noteref">â</a></td><td class="xbxx-borders">66 (2.2)</td><td class="xbxr-borders">70 (4.5)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Data in this table represent analyses through 180 day of postpartum follow-up for maternal participants and through 364 days of life for infant participants; there was a 14-day trial-visit window for both maternal and infant participants. Analyses were generated from the data obtained from the locked database as of September 27, 2019, and were performed in the safety analysis population (all maternal participants who had undergone randomization and received the RSV F vaccine or placebo and their live-born infants). MedDRA denotes <i>Medical Dictionary for Regulatory Activities</i>.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">Solicited adverse events were common postvaccinal adverse events that were solicited by diary from day 0 through day 6 after injection.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">Severe and related adverse events were those that substantially prevented the performance of normal daily activities and were assessed by the clinical investigators to be at least possibly related to the RSV F vaccine or placebo.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">Serious adverse events were those that were fatal or life-threatening, caused or prolonged hospitalization, led to persistent disability, or were congenital anomalies or birth defects. In this trial, all congenital anomalies, regardless of how minor, were treated as serious adverse events.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"><div class="label">Â¶</div></a><div id="core-t3fn5" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg">Protocol-defined adverse events of special interest were adverse events that occurred during pregnancy and the puerperium that reflected the recommendations of the Brighton Collaboration task forces regarding safety data collection for maternal immunization.<sup></sup></a><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="core-body-ref-r11" href-manipulated="true" aria-label="Reference 11" data-to-manipulate="false">11</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">Serious adverse events coded to the MedDRA preferred term âpneumoniaâ showed an imbalance between the trial groups that suggested a relative risk of 0.49 in infants of immunized maternal participants, which was associated with an unadjusted P value lower than 0.001. This P value is smaller than any other in the analyses of serious adverse events by more than 2 orders of magnitude (Table S10). Further details on solicited adverse events are provided in Table S4; on unsolicited adverse events that were reported in at least 1% of maternal or infant participants in Tables S5 and S6, respectively; on all serious adverse events in maternal and infant participants in Tables S9 and S10, respectively; and all protocol-specified adverse events of special interest in maternal and infant participants in Tables S7 and S8, respectively.</div></div></div></figcaption><figcaption><div class="caption">Safety Profile in Maternal and Infant Participants.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1908380_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1908380</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Shi T, McAllister DA, OâBrien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. <em>Lancet</em> 2017;390:946-958.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(17)30938-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28689664/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000408746300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global%2C+regional%2C+and+national+disease+burden+estimates+of+acute+lower+respiratory+infections+due+to+respiratory+syncytial+virus+in+young+children+in+2015%3A+a+systematic+review+and+modelling+study.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=946-958&amp;doi=10.1016%2FS0140-6736%2817%2930938-8&amp;pmid=28689664" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Pertussis vaccines: WHO position paper â September 2015. <em>Wkly Epidemiol Rec</em> 2015;90:433-458.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26320265/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pertussis+vaccines%3A+WHO+position+paper+%E2%80%94+September+2015.&amp;publication_year=2015&amp;journal=Wkly+Epidemiol+Rec&amp;pages=433-458&amp;pmid=26320265" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Vaccines against influenza: WHO position paper â November 2012. <em>Wkly Epidemiol Rec</em> 2012;87:461-476.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23210147/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Vaccines+against+influenza%3A+WHO+position+paper+%E2%80%94+November+2012.&amp;publication_year=2012&amp;journal=Wkly+Epidemiol+Rec&amp;pages=461-476&amp;pmid=23210147" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Tetanus vaccines: WHO position paper â February 2017. <em>Wkly Epidemiol Rec</em> 2017;92:53-76.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28185446/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tetanus+vaccines%3A+WHO+position+paper+%E2%80%94+February+2017.&amp;publication_year=2017&amp;journal=Wkly+Epidemiol+Rec&amp;pages=53-76&amp;pmid=28185446" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. <em>BMC Infect Dis</em> 2009;9:106-106.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2334-9-106" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19575815/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000269557800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+meta-analysis+of+the+effect+of+antibody+therapy+for+the+prevention+of+severe+respiratory+syncytial+virus+infection.&amp;publication_year=2009&amp;journal=BMC+Infect+Dis&amp;pages=106-106&amp;doi=10.1186%2F1471-2334-9-106&amp;pmid=19575815" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">OâBrien KL, Chandran A, Weatherholtz R, et al. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. <em>Lancet Infect Dis</em> 2015;15:1398-1408.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(15)00247-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26511956/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365144800026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+of+motavizumab+for+the+prevention+of+respiratory+syncytial+virus+disease+in+healthy+Native+American+infants%3A+a+phase+3+randomised+double-blind+placebo-controlled+trial.&amp;publication_year=2015&amp;journal=Lancet+Infect+Dis&amp;pages=1398-1408&amp;doi=10.1016%2FS1473-3099%2815%2900247-9&amp;pmid=26511956" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">MuÅoz FM, Swamy GK, Hickman SP, et al. Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants. <em>J Infect Dis</em> 2019;220:1802-1815.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/infdis/jiz390" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31402384/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000493469600013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+respiratory+syncytial+virus+fusion+%28F%29+protein+nanoparticle+vaccine+in+healthy+third-trimester+pregnant+women+and+their+infants.&amp;publication_year=2019&amp;journal=J+Infect+Dis&amp;pages=1802-1815&amp;doi=10.1093%2Finfdis%2Fjiz390&amp;pmid=31402384" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] efficiently transferred to the infants. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] assays may provide correlates of risk. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] times (95% CI, 17.84 to 19.36) as high. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">World Bank. World Bank country and lending groups. 2020 (<a href="https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups">https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=World+Bank.+World+Bank+country+and+lending+groups.+2020+%28https%3A%2F%2Fdatahelpdesk.worldbank.org%2Fknowledgebase%2Farticles%2F906519-world-bank-country-and-lending-groups%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">August A, Glenn GM, Kpamegan E, et al. A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. <em>Vaccine</em> 2017;35:3749-3759.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2017.05.045" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28579233/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404504900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+phase+2+randomized%2C+observer-blind%2C+placebo-controlled%2C+dose-ranging+trial+of+aluminum-adjuvanted+respiratory+syncytial+virus+F+particle+vaccine+formulations+in+healthy+women+of+childbearing+age.&amp;publication_year=2017&amp;journal=Vaccine&amp;pages=3749-3759&amp;doi=10.1016%2Fj.vaccine.2017.05.045&amp;pmid=28579233" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] F vaccine adsorbed to 0.4 mg of aluminum) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] times (95% CI, 17.84 to 19.36) as high. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Zou G. A modified Poisson regression approach to prospective studies with binary data. <em>Am J Epidemiol</em> 2004;159:702-706.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/aje/kwh090" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15033648/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000220484900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+modified+Poisson+regression+approach+to+prospective+studies+with+binary+data.&amp;publication_year=2004&amp;journal=Am+J+Epidemiol&amp;pages=702-706&amp;doi=10.1093%2Faje%2Fkwh090&amp;pmid=15033648" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Munoz FM Eckert LO, Katz MA, et al.Key terms for the assessment of the safety of vaccines in pregnancy: results of a global consultative process to initiate harmonization of adverse event definitions. <em>Vaccine</em> 2015;33:6441-6452.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2015.07.112" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26387433/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000367489300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Key+terms+for+the+assessment+of+the+safety+of+vaccines+in+pregnancy%3A+results+of+a+global+consultative+process+to+initiate+harmonization+of+adverse+event+definitions.&amp;publication_year=2015&amp;journal=Vaccine&amp;pages=6441-6452&amp;doi=10.1016%2Fj.vaccine.2015.07.112&amp;pmid=26387433" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 29, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2021648" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Disarming the Respiratory Syncytial Virus</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H.C. Meissner</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 29, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1913556" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.P. Griffin and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Portland, Maine</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/884067/clinical-cardiology-opportunity-advanced-imaging/?query=fjwp&amp;rid=1000">CLINICAL CARDIOLOGY OPPORTUNITY - Advanced Imaging</a></div></div><div class="nejm-widget_item"><div><span> Chestnut Hill, Massachusetts</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/877653/chief-medical-director-outpatient-adult-primary-care/?query=fjwp&amp;rid=980">Chief / Medical Director- Outpatient Adult Primary Care</a></div></div><div class="nejm-widget_item"><div><span> Poughkeepsie, New York</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883868/adult-epileptologist-midhudson-regional-hospital/?query=fjwf&amp;rid=22466">Adult Epileptologist - MidHudson Regional Hospital</a></div></div><div class="nejm-widget_item"><div><span> Center, Nebraska</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879131/hematologist-oncologist-210k-recruitment-incentive-and-attractive-work-schedule/?query=fjwf&amp;rid=764">Hematologist Oncologist - $210k+ Recruitment Incentive &amp; Attractive Work Schedule</a></div></div><div class="nejm-widget_item"><div><span> Abilene, Texas</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890036/hematologist-oncologist-texas-oncology-abilene/?query=fjwp&amp;rid=5696">Hematologist/Oncologist - Texas Oncology Abilene</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/880284/per-diem-physician-family-medicine/?query=fjwf&amp;rid=385607">Per Diem Physician - Family Medicine</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1908380&amp;pubId=41289580&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d63d29507a36ec-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d63d29507a36ec-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d63d29507a36ec-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$507380981$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$507380981$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$507380981$--></div></div><div class="mlt-body"><!--?lit$507380981$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$507380981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$507380981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$507380981$-->Apr 20, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2216480?query=recirc_Semantic" target="_self">Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants</a></div><div class="mlt-article-authors"><!--?lit$507380981$-->B. Kampmann and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$507380981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$507380981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$507380981$-->Feb 16, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2209604?query=recirc_Semantic" target="_self">Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults</a></div><div class="mlt-article-authors"><!--?lit$507380981$-->A. Papi and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$507380981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$507380981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$507380981$-->Apr 28, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2106062?query=recirc_Semantic" target="_self">Prefusion F ProteinâBased Respiratory Syncytial Virus Immunization in Pregnancy</a></div><div class="mlt-article-authors"><!--?lit$507380981$-->E.A.F. SimÃµes and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$507380981$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$507380981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$507380981$-->Sep 26, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313551?query=recirc_Semantic" target="_self">Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection</a></div><div class="mlt-article-authors"><!--?lit$507380981$-->S. Zhao and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$507380981$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$507380981$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$507380981$-->Sep 14, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2307729?query=recirc_Semantic" target="_self">Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants</a></div><div class="mlt-article-authors"><!--?lit$507380981$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1908380?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1908380" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1908380.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1908380"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa1913556" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1914735" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Uterine-Artery Embolization or Myomectomy for Uterine Fibroids</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f1.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/b179aa9e-55b8-462e-9a46-227c6d25f758/assets/images/large/nejmoa1908380_f1.jpg" height="3438" width="2629" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Enrollment, and Randomization.</div><div class="notes"><div role="doc-footnote">Data regarding the disposition and demographic characteristics of the participants, safety, and immunogenicity were obtained from the complete and locked database (date of data extraction, September 27, 2019). Efficacy data were obtained from the locked database after all the participants had completed the 180-day follow-up (date of data extraction, January 30, 2019); these data represented the official efficacy analysis set. The safety population comprised all maternal participants who had undergone randomization and received the respiratory syncytial virus fusion protein nanoparticle vaccine (RSV F vaccine) or placebo and their live-born infants. Data on exclusions are derived from incomplete informed consent documentation, lost or incomplete source documentation, or both. The intention-to-treat efficacy analysis population included all maternal participants and their infants in the safety analysis population for whom at least one respective post-treatment or postpartum efficacy measurement was available for both the mother and the infant, as evidenced by collection of surveillance observations. The maternal participants in the per-protocol efficacy analysis population were those who received the assigned RSV F vaccine or placebo, had at least one post-treatment encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. The infant participants in the per-protocol efficacy population were those who were born at 37 weeks or more of gestation, who were born to maternal participants who had undergone randomization and received the assigned vaccine or placebo at least 2 weeks before delivery, and who did not receive prophylactic treatment with palivizumab between the day of birth and day 180 after delivery, had at least one postpartum encounter with trial personnel during which active or passive surveillance (or both) for RSV illness could have been performed, and had no major protocol deviations affecting the primary efficacy end point, as determined and documented by the sponsor before database lock and unblinding. Participants who were excluded from one or more analysis populations may have had more than one of the listed major protocol deviations or exclusionary characteristics. Per-protocol status in an infant required elements of per-protocol performance in the mother.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1908380_f2.jpg"><img src="/cms/10.1056/NEJMoa1908380/asset/83a76d33-9b14-4838-ad0c-7155a60343b6/assets/images/large/nejmoa1908380_f2.jpg" height="3438" width="2276" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">KaplanâMeier Survival Plots for the Primary and Secondary Efficacy End Points in the Per-Protocol Population.</div><div class="notes"><div role="doc-footnote">Shown are the KaplanâMeier survival plots for the primary efficacy end point of RSV-associated, medically significant lower respiratory tract infection (Panel A) and the secondary efficacy end points of RSV-associated lower respiratory tract infection with severe hypoxemia (Panel B) and hospitalization for RSV-associated lower respiratory tract infection (Panel C). For each panel, the main figure depicts the percentage of infants in the per-protocol population who survived without the occurrence of the specified end-point event as a function of time from delivery. Because the events under study occurred in 5% of the infant population or less over the first 180 days of life, insets are provided to show the same data on an enlarged y axis.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Baseline Demographic Characteristics and Other Characteristics of the Maternal Participants and Birth and Household Characteristics of their Infants.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy of Maternal Vaccination against Lower Respiratory Tract Infection in Infants.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Safety Profile in Maternal and Infant Participants.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/5" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 5</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 30, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2000226" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Phase 1 Trial of a Therapeutic AntiâYellow Fever Virus Human Antibody</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.G. Low and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 30, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1914735" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Uterine-Artery Embolization or Myomectomy for Uterine Fibroids</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">I. Manyonda and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 30, 2020</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra1908213" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Treatment of Chronic Lymphocytic Leukemia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.A. Burger</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1908380%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1908380&amp;pubId=41289580&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1908380%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1908380&amp;pubId=41289580&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id007093913791735218" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d63d29507a36ec-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d63d29507a36ec-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d63d29507a36ec-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d63d29507a36ec-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d63d29507a36ec-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d63d29507a36ec-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d63d29507a36ec-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d63d29507a36ec-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d63d29507a36ec-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d63d29507a36ec-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d63d293be136ec',t:'MTc0OTUzMDkzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d63d293be136ec&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1908380?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><uad-ttxpuenqwjzf></uad-ttxpuenqwjzf><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-transactionid="nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" id="captureIFrame_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" target="captureIFrame_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="capture_screen"><input id="capture_signIn_js_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="js_version"><input id="capture_signIn_transactionId_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" type="hidden" class="capture_transactionId_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="capture_transactionId"><input id="capture_signIn_form_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="form"><input id="capture_signIn_flow_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="flow"><input id="capture_signIn_client_id_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="client_id"><input id="capture_signIn_redirect_uri_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="redirect_uri"><input id="capture_signIn_response_type_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="response_type"><input id="capture_signIn_flow_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="flow_version"><input id="capture_signIn_settings_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="settings_version"><input id="capture_signIn_locale_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="locale"><input id="capture_signIn_recaptcha_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_nsrald8x8v3vdpgv23kxn7vw2lhspyavikkitvby" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>